Glycosylation in cancer: mechanisms and clinical implications

Salomé S. Pinho[1–3] *and Celso A. Reis*[1–4]

Abstract | Despite recent progress in understanding the cancer genome, there is still a relative delay in understanding the full aspects of the glycome and glycoproteome of cancer. Glycobiology has been instrumental in relevant discoveries in various biological and medical fields, and has contributed to the deciphering of several human diseases. Glycans are involved in fundamental molecular and cell biology processes occurring in cancer, such as cell signalling and communication, tumour cell dissociation and invasion, cell–matrix interactions, tumour angiogenesis, immune modulation and metastasis formation. The roles of glycans in cancer have been highlighted by the fact that alterations in glycosylation regulate the development and progression of cancer, serving as important biomarkers and providing a set of specific targets for therapeutic intervention. This Review discusses the role of glycans in fundamental mechanisms controlling cancer development and progression, and their applications in oncology.

Glycome
The entire complement of glycan structures in an organism.

[1]*Instituto de Investigação e Inovação em Saúde (Institute for Research and Innovation in Health), University of Porto, Portugal.*
[2]*Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Rua Dr. Roberto Frias s/n, 4200–465 Porto, Portugal.*
[3]*Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira n.228, 4050–313 Porto, Portugal.*
[4]*Faculty of Medicine of the University of Porto, Alameda Prof. Hernâni Monteiro, 4200–319 Porto, Portugal.*
Correspondence to C.A.R.
e-mail: celsor@ipatimup.pt
doi:10.1038/nrc3982
Published online
20 August 2015

In recent years, glycobiology has gained increased importance in cancer research, given its role in understanding various cancer mechanisms and as it provides a set of targets for diagnostic application and therapeutic strategies[1–6].

Glycosylation can act as a key regulatory mechanism controlling several physiopathological processes. Defects in glycosylation in humans and their links to disease have shown that the mammalian glycome contains a remarkable amount of biological information[7]. Glycan diversity arises from differences in monosaccharide composition (for example, galactose (Gal) or *N*-acetylgalactosamine (GalNAc)), in linkage between monosaccharides (for example, between carbons 1 and 3 or carbons 1 and 4), in anomeric state, in branching structures, in other substitutions (such as sulfation state) and in linkage to their aglycone part (protein or lipid)[8,9] (FIG. 1). Characterizing the biological functions of each glycan[10], as well as those of glycan-binding proteins (including galectins and sialic acid-binding immunoglobulin-type lectins (siglecs)), has been shown to make important contributions to the cancer field[1–3,5]. Different types of glycoconjugates interfere with key cancer cell processes as well as with the tumour microenvironment, leading to cancer progression. This Review describes how glycans affect and regulate the genesis and progression of cancer. The recent cutting-edge technological developments in glycobiology and their innovative applications in the oncology field are also introduced and discussed.

Glycoconjugates and glycosylation

Glycosylation is defined as the enzymatic process that produces glycosidic linkages of saccharides to other saccharides, proteins or lipids[1,11]. Glycoconjugates are primarily defined according to the nature of and linkage to their aglycone (non-glycosyl) part (FIG. 1). Glycoproteins carry one or more glycans covalently attached to a polypeptide backbone, usually via nitrogen or oxygen linkages, in which case they are known as *N*-glycans or *O*-glycans, respectively[8,12,13] (FIG. 2).

A common type of protein *O*-glycosylation is initiated via GalNAc — the first monosaccharide that connects serine or threonine in particular forms of protein *O*-glycosylation (*O*-GalNAc) called mucin-type *O*-glycosylation[12,13] — which can be extended into various different structures[14]. There are other types of *O*-glycans as well, such as those attached via *O*-mannose, and the nucleocytoplasmic glycan *O*-linked β-*N*-acetylglucosamine (*O*-GlcNAc)[15] (FIGS 1,2).

In addition, other forms of glycosylation exist that occur only in specific types of proteins, such as the Notch receptor, and these have been shown to be important in cancer cell biology[16] (BOX 1). Moreover, several



Figure 1 | **Common classes of glycoconjugates in mammalian cells.** Glycans can be found in various types of macromolecules. Glycosphingolipids are major components of the outer leaflet of the cell plasma membrane. These ceramide-linked glycans are made of a variable series of structures that can be further modified with terminal sialic acids[8,17]. Proteins can be glycosylated by the covalently attachment of a saccharide to a polypeptide backbone, via *N*- linkage to Asp or *O*-linkage to Ser/Thr[8]. Mucin-type *O*-glycans are frequently found in secreted or membrane-associated glycoproteins and are initiated by *N*-acetylgalactosamine (GalNAc) *O*-linked to Ser/Thr[13]. *O*-glycans can be extended, producing various 'cores' and different terminal structures that are usually fucosylated and sialylated[14]. Other types of *O*-glycans include the *O*-mannose (*O*-Man), *O*-fucose (*O*-Fuc), *O*-galactose (*O*-Gal) and nucleocytoplasmic *O*-linked β-*N*-acetylglucosamine (*O*-GlcNAc)[11,15]. *N*-glycosylation occurs in the consensus peptide sequences Asn-X-Ser/Thr (in which X denotes any amino acid). *N*-glycans share a common pentasaccharide core region (highlighted in the figure as a dotted line box) that can be further diversified into oligomannose, hybrid or complex types and further modified by the terminal structures GlcNAc, Gal and sialic acid[8]. Some glycoproteins can also be found in the outer leaflet of the plasma membrane linked to a phosphatidylinositol; these are called glycosylphosphatidylinositol (GPI)-anchored proteins[8]. Glycosaminoglycans are linear co-polymers of acidic disaccharide repeating units mostly found attached to the so-called proteoglycans[8]. An exception is hyaluronic acid, which is a glycosaminoglycan found free in the extracellular matrix.

Anomeric state
The configuration (α or β) of the hydroxy group originating from the aldehyde or ketone group after monosaccharide ring closure.

Sialic acid-binding immunoglobulin-type lectins
(Siglecs). Proteins that bind sialic acid.

N-glycans
Oligosaccharides covalently linked to an Asp residue of a protein (at the consensus sequence Asn-X-Ser/Thr, in which X is any amino acid) via a nitrogen atom. *N*-glycans are classified into high-mannose, complex and hybrid types.

O-glycans
Oligosaccharides that are linked to a polypeptide via an oxygen atom. *O*-glycans are classified according to the initiating monosaccharide linked to a Ser or Thr residue.

Glycosaminoglycan
(GAG). A linear co-polymer containing acidic disaccharide repeating units attached to proteoglycans via xylose linked to the hydroxyl group of a Ser residue[8].

proteins are linked to the cell membrane through a glycosylphosphatidylinositol (GPI) anchor; these are known as GPI-anchored proteins[8] (BOX 2).

Other major classes of glycoconjugates include the proteoglycans and glycosphingolipids (FIG. 1). Proteoglycans are glycoconjugates that have one or more glycosaminoglycan (GAG), such as chondroitin sulfate, heparan sulfate and keratan sulfate[8]. Hyaluronan is a GAG primarily found as a free sugar chain.

Glycosphingolipids are molecules composed of a glycan linked to a lipid ceramide. The structural and functional classifications of glycosphingolipids have traditionally been based on their glycan part[8]. The first sugars linked to ceramide in higher animals are typically β-linked galactose (galactosylceramide) or glucose (glucosylceramide). In vertebrate glycosphingolipids, the glucose moiety is typically substituted with β-linked galactose, creating a lactosylceramide (D-galactosyl-1,4-β-D-glucosylceramide). Glycosphingolipids include a series of neutral 'core' structures and gangliosides, which typically carry one or several sialic acids and have been shown to regulate receptor tyrosine kinase (RTK) signalling[17].

Glycosylation alterations in cancer

Changes in glycosylation associated with oncogenic transformation were first described over more than six decades ago[18,19]. Those observations were further corroborated with the advent of monoclonal antibody technology, which showed that tumour-specific antibodies were directed against carbohydrate epitopes and, in most cases, were oncofetal antigens present on tumour glycoproteins and glycosphingolipids[20,21].

Tumour cells display a wide range of glycosylation alterations compared with their non-transformed counterparts. Protein glycosylation increases molecular heterogeneity as well as the functional diversity within cell populations (FIG. 2). This heterogeneity occurs because aberrant glycan modifications are protein-specific, site-specific (different sites on a given protein can be differentially glycosylated) and cell-specific. The specificities of glycosylation depend on various intrinsic factors of the glycosylation process within a given cell or tissue type. Two principal mechanisms underlying the tumour-associated alterations of carbohydrate structures were first postulated by Hakomori

and Kannagi, in the so-called incomplete synthesis and neo-synthesis processes[22]. The incomplete synthesis process, occurring more often in early stages of cancer, is a consequence of the impairment of the normal synthesis of complex glycans expressed in normal epithelial cells, which leads to the biosynthesis of truncated structures, as seen with sialyl Tn (STn) expression in gastrointestinal and breast cancers[23,24]. Conversely, neo-synthesis, commonly observed in advanced stages of cancer, refers to the cancer-associated induction of



Chondroitin sulfate
A GAG chain containing acidic disaccharide repeating units of *N*-acetylgalactosamine β1-4 glucuronic acid (GlcNAcβ1-4GlcA). The GAG is called dermatan sulfate when the repeating units is *N*-acetylgalactosamine β1-4 iduronic acid (GlcNAcβ1-4IdoA).

Heparan sulfate
A GAG chain containing acidic disaccharide repeating units of *N*-acetylgalactosamine α1-4 glucuronic acid or iduronic acid (GlcNAcα1-4GlcA or GlcNAcα1-4IdoA).

Keratan sulfate
A GAG chain containing acidic disaccharide repeating units of galactose β1-4-*N*-acetylglucosamine (Galβ1-4GlcNAc).

Glycosyltransferases
Enzymes that catalyse the transfer of saccharides (sugars) from activated donors to acceptor molecules (proteins, lipids or carbohydrates), forming covalent bonds.

certain genes involved in the expression of carbohydrate determinants, as seen in the *de novo* expression of certain antigens (such as sialyl Lewis a (SLe^a) and SLe^x) in many cancers[25].

In general, a shift from the normal glycosylation pathway occurs in cancer cells, leading to altered glycans expression owing to one or various factors. First, altered expression of glycans can be attributed to under- or overexpression of glycosyltransferases (owing to dysregulation at the transcriptional level[25–28], dysregulation of chaperone function[29,30] and/or altered glycosidase activity[31]). Second, altered glycan expression can be due to changes in the tertiary conformation of the peptide backbone and that of the nascent glycan chain. Third, the differences can stem from the variability of various acceptor substrates as well as the availability and abundance of the sugar nucleotide donors and cofactors[32]. Finally, changes in glycan expression can be due to the expression and localization of the relevant glycosyltransferases in the Golgi apparatus[33,34].

Mislocalization and/or changes in the activity of the glycosyltransferases results in the synthesis of immature core glycan structures[35,36]. Studies have shown that early acting enzymes synthesizing core *O*-glycans, such as GalNAc transferases, core 1 GalNAc β1,3-ga lactosyltransferase 1 (C1GalT1) and core 2 β1,6-*N*-acetylglucosaminyltransferase (C2GnT), are enriched in *cis*- and medial-Golgi cisternae[34,37], whereas late-acting enzymes (such as sialyltransferases) are enriched in *trans*-Golgi cisternae. In cells, overexpression of α-GalNAc α-2,6-sialyltransferase I (ST6GalNAc-I; encoded by *ST6GALNAC1*), the enzyme responsible for STn biosynthesis[23,24,38], leads to expression of enzymes in all Golgi cisternae and disrupts glycosylation by prematurely adding sialic acid to form the STn antigen[36,38].

The most-widely occurring cancer-associated changes in glycosylation are sialylation, fucosylation, *O*-glycan truncation, and *N*- and *O*-linked glycan branching[2,39,40] (FIGS 2,3).

Sialylation. Sialylation is an important modification in cellular glycosylation, as sialylated carbohydrates have an important role in cellular recognition, cell adhesion and cell signalling. An increase in global sialylation — especially in α2,6- and α2,3-linked sialylation — owing to altered glycosyltransferases expression has been closely associated with cancer[41].

The lactosaminic chains are frequently terminated with a sialic acid. For example, α2,6-sialylated lactosamine (Sia6LacNAc) is the product of β-galactoside α2,6-sialyltransferase I (ST6Gal-I)[42], an enzyme with altered expression in various malignancies — including colon, stomach and ovarian cancer[42] — and that has been reported to be a predictive marker of poor prognosis in colon cancer[43].

Other major sialylated antigens associated with cancer are SLe^a and SLe^x (REF. 2) (FIG. 2). SLe^a and SLe^x have been demonstrated to be highly expressed in many malignant cancers, and SLe^x expression levels have been correlated with poor survival in cancer patients[44,45].

SLe^x is the well-known ligand for selectins[46], which are vascular cell adhesion molecules that belong to a family of C-type lectins (which require calcium for binding). During inflammation, selectins mediate the initial attachment of leukocytes to the endothelium during the process of leukocyte extravasation[46]. In cancer, SLe^x interactions with selectins regulate the metastatic cascade by forming emboli of cancer cells and platelets and favouring their arrest on endothelia (FIG. 4), therefore determining the malignant behaviour and development of metastasis[47]. Tumour metastasis has been shown to be attenuated in animal models by the use of specific GAGs, such as heparin, that inhibit P-selectin-mediated interactions of platelets with carcinoma cell-surface ligands[48].

The SLe^a tetrasaccharide, which is detected by the serological assay CA19-9, is a cancer-associated marker widely used in the clinical practice. The CA19-9 assay has been mostly applied in patients with an established diagnosis of pancreatic, colorectal, gastric or biliary cancer and used to monitor clinical response to therapy[3,49]. In addition, elevated preoperative concentrations of CA19-9 have been shown to be associated with poor prognosis in colon and gastric carcinoma[50].

Increased sialylation in cancer also includes the expression of polysialic acid, which is associated with several types of cancers and is frequently expressed in high-grade tumours[51,52]. Polysialic acid can often be present in neural cell adhesion molecule 1 (NCAM1), and this is associated with aggressiveness and poor clinical outcome in cancers, including lung cancer, neuroblastoma and gliomas[51,52].

Gangliosides are also overexpressed in tumours such as melanoma, neuroblastoma and breast cancer, in which they mediate cell proliferation, tumour growth and cancer cell migration[17,53].

Fucosylation. Fucosylation has been also associated with cancer. Fucosylated glycans are synthesized by a range of fucosyltransferases (Fuc-Ts; Fuc-TI–Fuc-TXI (encoded by *FUT1–FUT11,* where *FUT3* is also known as the Lewis gene, Le)), with fucosylation existing as a non-extendable modification and being generally subdivided into terminal fucosylation (giving rise to specific Lewis blood-group antigens, such as Le^x and Le^y,

◀ Figure 2 | **Schematic representation of important glycan structures.** The figure represents specific *N*-linked (**a**) and *O*-linked (**b**) glycan structures, as well as the terminal Lewis and sialylated Lewis structures (**c**). The key enzymes responsible for the addition of specific sugar residues are also shown in blue boxes. Examples include the polypeptide *N*-acetylgalactosamine transferases (ppGalNAc-Ts; a family of 20 enzymes, including GalNAc-T1, GalNAc-T2, GalNAc-T3, GalNAc-T4, GalNAc-T5 and GalNAc-T6), sialyltransferases (such as α-galactoside α-2,6-sialyltransferase I (ST6Gal-I), α2,3-sialyltransferases (ST3Gal-Ts) and α-GalNAc ST6Gal-I (ST6GalNAc-I)), *N*-acetylglucosamine (GlcNAc) transferases (GnTs; such as GnT-III, GnT-V, core 2 GnTs (C2GnTs) and β3GnT) and fucosyltransferases (Fuc-Ts). The latter include Fuc-TVIII (which mediates the addition of 'core' α1,6Fuc to *N*-glycans); Fuc-TI and Fuc-TII, which add fucose (Fuc) in α1,2 linkage to galactose (Gal); Fuc-Ts that mediate the addition of Fuc in α1,3 linkage to an α2,3-sialylated type 2 chain (Fuc-TIII, Fuc-TIV, Fuc-TV, Fuc-TVI, Fuc-TVII and Fuc-TIX); and Fuc-Ts that add Fuc in α1,4 linkage to an α2,3-sialylated type 1 chain (Fuc-TIII and Fuc-TV). The blue boxes highlighted in part **c** show the carbohydrate terminal Lewis antigens. Lewis type 1 antigens includes Lewis a (Le^a), Le^b and sialyl Lewis a (SLe^a); the type 2 group includes Le^x, Le^y and SLe^x. C1GalT1, core 1 GalNAc β1,3-GalT 1; GalT, galactosyltransferase; GlcA, glucuronic acid; Man, mannose; STn, sialyl Tn.

Box 1 | **The unique type of Notch glycosylation**

Notch signalling is essential for cell fate, and dysregulation of the pathway leads to various human diseases, including cancer[96]. Glycosylation of the Notch extracellular domain has been shown to regulate Notch activity[96]. The Notch ligands (the Delta, Serrate and LAG-2 family of proteins) bind to the extracellular domain of Notch receptor, triggering its activation by inducing a conformational change that exposes cleavage sites in Notch. Cleavage at these sites results in liberation of the Notch intracellular domain, which translocates to the nucleus and controls the transcriptional activation of the transcription factor recombining binding protein suppressor of hairless (RBP-Jκ). The Notch extracellular domain is modified with different types of carbohydrates, including Asp-linked *N*-glycans and several *O*-glycans, such as *O*-fucose[208]. *O*-fucose monosaccharides are elongated to a *N*-acetylglucosamine β1-3fucose (GlcNAcβ1-3Fuc) disaccharide by the action of the Fringe *N*-acetylglucosaminyltransferase in *Drosophila melanogaster* and by the Fringe homologues in vertebrates[96,209]. The disaccharide can be further elongated to the tetrasaccharide Neu5Acα2-3/6Galβ1-4GlcNAcβ1-3Fuc by the sequential action of several glycosyltransferases in mammals[96].

Fringe was demonstrated to be a modulator of Notch activity[209]. Three Fringe homologues exist in mammals: lunatic fringe, manic fringe and radical fringe[210]. Notch regulation by glycosylation, such as the addition of GlcNAc by Fringe, was shown to interfere with Notch–ligand interactions, promoting Notch–Delta binding and reducing Notch–Serrate binding[96,209].

Several studies have reviewed the mechanisms of glycosylation in the regulation of this important receptor in cancer[96]. Glycosylation-dependent modulation of Notch signalling controls development, maintains tumour cell 'stemness' and mediates cancer metastasis[96].

and Le^a and Le^b) and core fucosylation[54]. The terminal steps of the biosynthesis of SLe antigens include the α1,3- or α1,4-fucosylation of a previously α2,3-sialylated type 1 (SLe^a) or type 2 (SLe^x) chains[54,55] (FIG. 2). The enhanced expression of SLe^x in adult T cell leukaemia cells has been shown to be dependent on Fuc-TVII activity. The aetiologic agent of this leukaemia, the human T-lymphotropic virus 1 (HTLV-1) retrovirus, encodes a transcriptional activator protein, TAX, which regulates the *FUT7* gene encoding Fuc-TVII, the limiting enzyme controlling SLe^x synthesis in leukocytes[56].

In breast tumours, the expression of SLe^x seems to be regulated mainly by Fuc-TVI (encoded by *FUT6*)[57]. However, the biosynthesis of SLe antigens in gastrointestinal cancer may depend on the coordinated expression of several glycosyltransferases. The expression of both SLe^x and SLe^a antigens expressed by glycolipids in colon cancer tissues has been related to the activation of a β1,3GlcNAc transferase; this enzyme synthesizes a sugar chain that is a precursor for both type 1 and 2 Lewis structures[58]. A similar mechanism was observed in gastritis induced by *Helicobacter pylori*[59,60], a bacterium that expresses adhesins that recognize glycan receptors expressed by the gastric epithelium subsequently causing gastric ulcers and, potentially, gastric carcinogenesis[5] (BOX 3). Fuc-TVI has also been reported as a major enzyme modulating the SLe^x biosynthesis in colorectal cancer (CRC)[61].

Core fucosylation consists in the addition of α1,6-fucose to the innermost GlcNAc residue of *N*-glycans through the action of Fuc-TVIII (encoded by *FUT8*) (FIG. 2). Overexpression of *FUT8* and core fucosylation is an important feature in several cancers, such as lung cancer and breast cancer[62,63]. This increased core fucosylation is reflected in the serum levels during the process of hepatocarcinogenesis[64]. Interestingly, core fucosylation of α-fetoprotein is an approved biomarker for the early detection of hepatocellular carcinoma (HCC), distinguishing it from chronic hepatitis and liver cirrhosis[65]. In breast cancer, increased core fucosylation of epidermal growth factor receptor (EGFR) was associated with increased dimerization and phosphorylation, which resulted in increased EGFR-mediated signalling associated with tumour cell growth and malignancy[62,66].

Branching and bisecting GlcNAc N-glycans. During malignant transformation, a frequently occurring glycosylation change in cancer cells is the increased expression of complex β1,6-branched *N*-linked glycans[2,67] (FIGS 2,3). Increased GlcNAc-branching *N*-glycan expression is due to increased activity of GnT-V, which is encoded by the mannoside acetylglucosaminyltransferase 5 (*MGAT5*) gene. *MGAT5* expression is regulated by the RAS–RAF–MAPK signalling pathway, which is activated in cancer[67]. Branched *N*-glycans are further modified by β1,4-GalTs and elongated with poly-*N*-acetyllactosamine (repeats of Galβ1,4GlcNAcβ1,3) by β1,3-GnTs, and further capped with sialic acid and fucose. This poly-*N*-acetyllactosamine structure is a ligand for galectins, a family of conserved carbohydrate-binding proteins, which form galectin–glycan structures termed 'lattices' (REF. 68). Galectins have important roles in cancer, contributing to neoplastic transformation, tumour cell survival, angiogenesis and tumour metastasis[69]. Overexpression of *MGAT5* in an immortalized lung epithelial cell line resulted in loss of contact inhibition, increased cell motility and tumour formation in athymic mice[70], as well as in enhanced invasion and metastasis in mouse mammary carcinoma cells[71]. Moreover, early events in breast carcinoma formation in a *Her2*-transgenic mouse mammary tumour model were found to be regulated by GnT-V[72]. In addition, downregulation of GnT-V in mouse mammary cancer cell lines resulted in a significant suppression of tumour growth and metastasis[71]. Breast cancer progression and metastasis induced by a viral oncogene in transgenic mice is markedly suppressed in *Mgat5*-deficient background[73]. Moreover, GnT-V-mediated glycosylation regulates the colon cancer stem cell compartment and tumour progression through WNT signalling[74].

In contrast to the function of GnT-V, GnT-III (encoded by *MGAT3*) catalyses the addition of bisecting GlcNAc *N*-glycans in a β1,4-linkage, suppressing additional processing and elongation of *N*-glycans such as the β1,6-branching structures. GnT-III counteracts the role of GnT-V in cancer, being involved in the suppression of cancer metastasis[75]. *MGAT3* transfection into mouse melanoma B16 cells with high metastatic potential resulted in a significant reduction of β1,6GlcNAc branching (owing to GnT-III and GnT-V enzymatic competition), leading to a significant suppression of lung metastasis in mice. GnT-III suppresses

tumour metastasis through the regulation of key glycoproteins, such as EGFR, integrins and cadherins[66,76], as described below.

Truncated O-glycans. Another common feature of tumours is the overexpression of truncated *O*-glycans (FIGS 2,3). The GalNAc-type *O*-glycans, also called mucin-type *O*-glycans, are frequently found in most transmembrane and secreted glycoproteins. During malignancy, aberrant glycosylation also occurs in glycoproteins that display abnormal expression of shortened or truncated glycans, such as the disaccharide Thomsen–Friedenreich antigen (T antigen, also known as core 1) and the monosaccharide GalNAc (also known as Tn) and their sialylated forms (ST and STn (Neu5Acα2-6GalNAcα-*O*-R), respectively), which result from the incomplete synthesis of *O*-glycans[77].

Altered expression of polypeptide GalNAc transferases (ppGalNAcTs) — the enzymes initiating the mucin-type *O*-glycosylation[12,13] — is often observed in cancer[78,79]. The ppGalNAcTs control the sites and density of *O*-glycan occupancy[12,13], and changes in their expression lead to alterations in *O*-glycosylation[80]. In addition, enzymes competing for the same substrate can also induce expression of truncated glycans and exposure of protein epitopes that would otherwise be hidden in the normally glycosylated protein. The relative enzymatic activities of C2GnT and α2,3-sialyltransferase I (ST3Gal-I) have been shown to determine the *O*-glycan structure in cancer cells[81]. These relative activities underlie the aberrant expression of a tumour-associated epitopes on glycoproteins, such as mucins in breast[81] and gastric[82] cancers. STn is rarely expressed in normal healthy tissues but can be detected in most carcinomas, such as those from the pancreas[83,84], stomach[23,85,86], colorectum[23,87], breast[38], bladder[88] and ovary[89], correlating with decreased cancer cell adhesion, increased tumour growth, increased tumour cell migration, invasion and poor prognosis. The abnormal synthesis of STn in cancer occurs owing to the overexpression of ST6GalNAc-I. Mutations in T-synthase C1GalT1-specific chaperone 1 (C1GALT1C1) — which blocks further *O*-glycan elongation and shifts the pathway towards generation of Tn — can also lead to STn expression through the action of ST6GalNAc-I[90,91] (FIG. 2). Therefore, STn has been proposed as an important prognostic marker and a target for the design of anticancer vaccines[92,93].

Glycosylation in the cancer cell

Glycans have been found to participate in numerous fundamental biological processes involved in cancer, such as inflammation (BOX 3), immune surveillance, cell–cell adhesion[76,94,95], cell–matrix interaction[76], inter- and intracellular signalling[96–99], and cellular metabolism[100,101] (FIG. 4). Furthermore, glycans alter protein conformation and structure, thereby modulating the functional activity of the protein[102]. Unravelling the biological significance of glycan-based interactions in cancer can contribute to the deciphering of molecular mechanisms underlying the biology of cancer.

Glycosylation in tumour cell–cell adhesion. The development of malignant tumours is in part characterized by the ability of a tumour cell to overcome cell–cell adhesion and to invade surrounding tissue. Epithelial cadherin (E-cadherin) is a transmembrane glycoprotein[103] and a major epithelial cell–cell adhesion molecule in cancer[104]. Glycans can have a profound effect on tumour cell–cell adhesion by directly interfering with E-cadherin functions.

GnT-V overexpression in gastric cancer cells induces E-cadherin cellular mislocalization from the cell membrane into the cytoplasm and its functional impairment[94,95]. The addition of GnT-V-mediated β1,6GlcNAc-branched *N*-glycans to E-cadherin leads to incorrectly assembled and non-functional adherens junctions, which compromise cell–cell adhesion[94,95,105] and downstream signalling pathways[106], contributing to tumour invasiveness and metastases[107]. Preventing this aberrant glycosylation in a specific Asp site improves E-cadherin functions in cancer[108]. Interestingly, patients with gastric carcinoma displaying loss of E-cadherin function (not explained at the genetic or structural level) exhibit an increase in β1,6GlcNAc-branched *N*-glycans on E-cadherin[5,94].

Conversely, GnT-III-mediated bisecting GlcNAc *N*-glycans counteract GnT-V activity through E-cadherin regulation[75,94]. This E-cadherin glycan modification was associated with a delayed turnover rate at cell membrane[94,109], inhibition of endocytosis[94], decreased phosphorylation of β-catenin that remained in complex with E-cadherin[110], and increased stability of adherens junctions, promoting tumour suppression[5,94,95]. Moreover, expression of GnT-III is also associated with suppression of epithelial-to-mesenchymal transition[28,111].

Therefore, a mutual regulatory mechanism between E-cadherin-mediated cell–cell adhesion and its glycosylation exists in cancer, which is controlled by the competitive action of GnT-III and GnT-V, and can culminate in either tumour suppression or tumour metastasis, respectively[5,112] (FIG. 4).

Cancer cells produce increased levels of sialylated glycans, leading to the high expression of tumour-associated antigens[2,113]. Increased expression of sialylated antigens promotes cell detachment from the

Box 2 | **GPI-anchored proteins and disease**

Glycosylphosphatidylinositol (GPI)-anchored proteins are formed by a glycan bridge between phosphatidylinositol and a phosphoethanolamine, which is then linked to the carboxy-terminal amino acid of a protein. This structure typically constitutes the only anchor to the lipid bilayer membrane for some proteins[8]. Mutation in the GPI phosphatidylinositol *N*-acetylglucosaminyltransferase subunit A (*PIGA*) gene leads to defects in the synthesis of the GPI anchor, resulting in deficiency of all GPI-bound proteins. Haematopoietic stem cells that are defective in GPI anchor assembly owing to a mutation in the *PIGA* gene preferentially expand in the bone marrow and give rise to defective peripheral blood elements that are deficient in GPI-anchored protein expression. Mutation in the X-linked *PIGA* gene causes paroxysmal nocturnal haemoglobinuria, a disease characterized by haemolytic anaemia, thrombosis and impaired bone marrow function, with an increased risk of developing leukaemia[211].



Figure 3 | **Important tumour-associated glycans.** Tumour cells often display glycans with different structures and levels of expression compared with their normal counterparts. These tumour-specific glycans are considered a hallmark of cancer cells. The most-widely occurring changes in glycosylation associated with cancer include an increase in overall sialylation[2,25]. Aberrant glycosylation in cancer frequently involves an increase in sialyl Lewis x (SLe^x) and SLe^a (REF. 41) antigens, as well as an increase in terminal α2,6-sialylated structures, both in truncated *O*-linked glycans (such as sialyl Tn (STn))[23,35,38] and in *N*-linked glycans[113], and an increase in the α2,8-linked polymer known as polysialic acid[52]. Moreover, certain sialic acid-containing glycosphingolipids called gangliosides (including monosialogangliosides, such as GM3 and GM1a, disialogangliosides, such as GD1a, GD2 and GD1b, and trisialogangliosides, such as GT1b) have been associated with malignancy[17]. Another broadly occurring change in glycosylation associated with cancer is an enhancement of β1,6-*N*-acetylglucosamine (β1,6GlcNAc)-branched structures in *N*-linked glycans caused by an increased activity of *N*-acetylglucosaminyltransferase V (GnT-V)[67]. Overexpression of 'core' fucosylation (the addition of α1,6-fucose (α1,6-Fuc) to the innermost GlcNAc of *N*-glycans) by fucosyltransferase VIII (Fuc-TVIII) is also considered an important event in tumour development and progression[196].Gal, galactose; GalNAc, *N*-acetylgalactosamine; Man, mannose.

tumour mass through electrostatic repulsion of negative charges, which physically inhibits and disrupts cell–cell adhesion[114,115]. Transfection of breast cancer cells with ST6Gal-I results in increased cell migration and decreased cell–cell adhesion *in vitro*[116] (FIG. 4). Furthermore, sialylated glycans (such as SLe^x) can promote the adhesion of tumour cells to vascular endothelial cells through their interaction with selectins, such as E-selectin, mediating the initial steps of the formation of cancer metastases[2] (FIG. 4). In addition, *de novo* expression of STn in gastric carcinoma cells modulates the malignant phenotype, inducing more-aggressive cell behaviour, with decreased cell–cell aggregation and increased matrix interaction, migration and invasion[85]. RNA interference-mediated gene silencing of *ST6GALNAC1* suppresses the metastatic potential of gastric cancer cells owing to a reduction in expression of insulin growth factor I (IGF-I) and reduced activation of signal transducer and activator of transcription, STAT5B [117]. Furthermore, somatic mutations and hypermethylation of *C1GALT1C1* have shown that loss of C1GALT1C1 function leads to STn expression, preventing cell–cell interactions and contact inhibition of cell growth in cancer cells[84]. Clinically, increased sialylation is often associated with invasiveness and poor prognosis of cancer patients[44,47].

Glycosylation in cell–matrix interaction and signalling. The extracellular matrix (ECM) is composed of a dynamic and complex array of glycoproteins, collagens, GAGs and proteoglycans. It provides mechanical and structural support, as well as spatial context, for signalling events, with direct implications in tumour development, maintenance of stem cell niches and cancer progression[118].

Heparan sulfate proteoglycans (HSPGs) are present on the cell surface and in the ECM and can modulate cell growth and differentiation, controlling embryogenesis, angiogenesis and homeostasis. HSPGs contain one or more covalently attached heparan sulfate GAG chains[119]. There are different groups of HSPGs classified according to their location: membrane HSPGs, such as syndecans and the GPI-anchored proteoglycans, the glypicans; the ECM HSPGs, such as agrin, perlecan and type XVIII collagen; and the secretory-vesicle HSPG, serglycin[119]. HSPGs can bind cytokines, chemokines and growth factors, protecting them against proteolysis; in addition, HSPGs can act as co-receptors for various growth factors for tyrosine kinase receptors, lowering their activation thresholds or changing the duration of their signalling reactions[119] (FIG. 4).

Overexpression of proteoglycans occurs in several cancers in which the heparan sulfate chains covalently bound to the proteoglycans can modulate the activation



Figure 4 | **Role of glycans in cancer development and progression.** Glycans play fundamental parts in key pathological steps of tumour development and progression. In the process of tumour cell dissociation and invasion, glycans interfere with cell–cell adhesion. The modification of epithelial cadherin (E-cadherin) with β1,6-*N*-acetylglucosamine (β1,6GlcNAc)-branched *N*-glycan structures through enhanced *N*-acetylglucosaminyltransferase V (GnT-V) activity impairs cell adhesion and promotes tumour cell invasion[94]. These branched structures can be extended and the α2,6-sialylated terminal structures interfere with tumour cell adhesion. The presence of E-cadherin *N*-glycans with bisecting GlcNAc structures catalysed by GnT-III leads to protein stability and suppression of tumour progression[75,94,95]. Aberrant *O*-glycosylation, such as expression of sialyl Tn (STn) owing to overexpression of α-*N*-acetylgalactosamine (α-GalNAc) α-2,6-sialyltransferase I (ST6GalNAc-I)[36,38] or mutations in C1GalT1-specific chaperone 1 (*C1GALT1C1*), is also associated with tumour cell invasion[84,85]. The process of tumour growth and proliferation is characterized by altered glycosylation of key growth factors receptors, which modulates their activity and signalling[161]. Expression of gangliosides in the cancer cell membrane can also modulate signal transduction, activating various cellular pathways that induce tumour growth and progression[17]. Altered *O*-GlcNAcylation is also associated with cancer progression[153]. In the process of tumour cell migration, integrins show altered glycosylation in both *O*-linked and *N*-linked glycans[76]. Terminal sialylation interferes with cell–extracellular matrix (ECM) interactions, promoting an increased migratory and invasive phenotype[140]. The aberrant glycosylation of vascular endothelial growth factor receptor (VEGFR) modulates its interaction with galectins and is associated with tumour angiogenesis[69]. The tumour-associated carbohydrate determinants sialyl Lewis x (SLe^x) and SLe^a serve as ligands for the adhesion receptors expressed in activated endothelial cells (E-selectin), platelets (P-selectin) and leukocytes (L-selectin), promoting cancer cell adhesion and metastasis[46]. Fuc, fucose; Gal, galactose; GlcA, glucuronic acid; Man, mannose; RTK, receptor tyrosine kinase; Xyl, xylose.

of protein receptors, such as HER2, EGFR, MET (also known as hepatocyte growth factor receptor (HGFR)) and transforming growth factor-β (TGFβ)[120]. Heparan sulfate chains regulate the interactions[121], and increase the solubility, of various signalling molecules[122], therefore increasing their access to receptors and facilitating signal transduction. For instance, heparan sulfate chains can release HGF, inducing cell growth and motility through interaction with MET[121], which is frequently activated in cancer cells[99] (FIG. 4). Heparan sulfate chains can also

release vascular endothelial growth factor A (VEGFA), a regulator of angiogenesis that stimulates growth, motility, and tubulogenesis in vascular endothelial cells through interactions with VEGF receptor 1 (VEGFR1) and VEGFR2 (REF. 121).

Another important membrane receptor involved in matrix-dependent cell motility and migration is CD44, which is the main receptor for hyaluronic acid. CD44 is a multifunctional cell surface molecule involved in cancer cell proliferation, differentiation, migration and signalling[123]. CD44 splicing variants have been associated with tumour development and progression[124]. The role of CD44 glycosylation in matrix-dependent cell adhesion, motility and migration is far from being elucidated. Nevertheless, evidence has shown that changes in glycosylation of CD44 can markedly influence hyaluronic acid ligand recognition and binding, modifying cancer cell signalling[125]. Treatments of CD44 with inhibitors of glycosylation and de-glycosylating enzymes significantly change the binding to hyaluronic acid, modulating CD44-dependent signalling and function[126]. Moreover, glycosylation modification of CD44 induced by transfection of α1,2–Fuc-T enhanced cell motility and tumorigenicity in rat carcinoma cells[127]. Additionally, GAG forms of CD44 containing chondroitin and heparin sulfate chains modulate the binding of tumour cells to fibronectin[128]. Proteoglycans are also involved in the biogenesis and recognition of exosomes, which are secreted vesicles of endosomal origin involved in signalling processes[129]. Syndecans control the interaction with key accessory components of the endosomal-sorting complexes required for transport machinery. In addition, heparanase modulates syndecan-controlled pathways, fostering endosomal membrane budding and the biogenesis of exosomes by trimming the heparan sulfate chains on syndecans and controlling the selection of specific cargo to exosomes[129]. Hyaluronidases also have many roles in cancer metastasis by participating in the degradation of the ECM surrounding the tumour, enabling cancer cells to disseminate from the primary tumour and allowing invasion by degradation of the basement membrane and by clearing the ECM of the secondary site[130].

Recent studies demonstrated that expression of bulky glycoproteins in the cancer cell glycocalyx facilitates integrin clustering by funnelling active integrins into adhesions and by applying tension to matrix-bound integrins, independently of actomyosin contractility[131]. Expression of large tumour-associated glycoproteins in non-transformed cells facilitates integrin-dependent growth factor signalling to support cell survival, further confirming that alterations of glycoprotein expression in the cancer cell glycocalyx could foster invasion and metastasis by mechanically enhancing cell-surface receptor function[131].

Cell–ECM interactions play essential parts during the acquisition of migration and invasive behaviour of tumour cells[132]. Integrins are carriers of *N*-glycans and are important receptors for signals in the ECM and connect many biological functions, such as cell proliferation, protection against apoptosis and malignant transformation[131]. Integrin expression is upregulated in migratory cells associated with tumour metastases[133]. *N*-glycans on α5β1 integrin, a receptor for fibronectin (encoded by *FN1*), are required for αβ-heterodimer formation and for proper integrin–matrix interaction[76]. Changes in *N*-glycans in cancer can regulate integrins functions. Transformation of NIH3T3 cells with an oncogenic *RAS* gene resulted in enhancement of cell spreading on fibronectin due to increased modification of α5β1 integrins with β1,6GlcNAc-branching *N*-glycans[134] through the upregulation of the RAS–RAF–MAPK signalling pathway and subsequent activation of *MGAT5* transcription. Similarly, overexpression of human fibrosarcoma cells with GnT-V resulted in an increased cell migration towards fibronectin and invasion through the Matrigel due to an increase in β1,6-branching *N*-glycans on α5β1 integrin[135]. Moreover, the characterization of carbohydrate moieties of α3β1 integrin, the receptor for laminin-5 showed that β1,6GlcNAc-branched structures were highly expressed in metastatic human melanoma cells[136].

Changes in *N*-linked β1,6-branching occurring during oncogenesis alter cell–matrix adhesion and migration by inhibiting the clustering of integrins and subsequent signal transduction pathways[136]. In contrast to the overexpression of GnT-V, the overexpression of GnT-III resulted in an inhibition of α5β1 integrin-mediated cell spreading and migration, and the phosphorylation of focal adhesion kinase (FAK). The affinity of the binding

Box 3 | **Glycosylation at the interface of inflammation-induced cancer**

During inflammation, a considerable number of glycosylation changes occur, and some of these have been associated with the carcinogenesis process. *Helicobacter pylori*, a Gram-negative bacterium specialized in the colonization of the human stomach, can cause gastric ulcers, and persistent infection may cause chronic atrophic gastritis with the development of intestinal metaplasia, dysplasia and gastric carcinoma[5]. The adhesion of *H. pylori* to the gastric mucosa is mediated by different bacterial adhesins that recognize glycans expressed by the gastric mucosa. The antigen-binding adhesin BabA binds to fucosylated antigens normally expressed by secretor individuals[212], and the sialic acid-binding adhesin SabA recognizes sialylated Lewis glycans (sialyl Lewis a (SLe^a) and SLe^x) expressed in gastritis[213]. Inflammation-induced glycosylation alterations, such as the aberrant overexpression of SLe^x, occur because of changes in glycosyltransferases expression[59,60,214]. Changes in glycosylation have also been studied in acute-phase proteins, such as α1 antitrypsin, as potential biomarkers in cancer and in acute and chronic inflammatory conditions[215]. Furthermore, glycosylation alterations have been shown to correlate with disease severity in certain inflammatory conditions, such as in inflammatory bowel disease[216]. In addition, glycosylation alterations have been reported in circulating proteins produced by the liver in patients with inflammatory diseases, such as gastritis[203] and pancreatitis[215].

Several studies have shown that the sialic acid *N*-glycolylneuraminic acid (Neu5Gc) is enriched in red meat, an epidemiological risk factor for cancer development[217]. Humans cannot synthesize Neu5Gc because the human gene cytidine monophosphate-*N*-acetylneuraminic acid hydroxylase (*CMAH*), which encodes the enzyme responsible for the synthesis of CMP-Neu5Gc from CMP-*N*-acetylneuraminic (CMP-Neu5Ac) acid is irreversibly mutated. The active form of CMAH is found in apes[218], and the mutated CMAH form is estimated to have originated 2–3 million years ago, prior to the emergence of the genus *Homo*[218]. Neu5Gc has been shown to be bioavailable, undergoing metabolic incorporation into human tissues. Human-like *Neu5Gc*-deficient mice have been shown to develop inflammatory conditions when fed with Neu5Gc and challenged with Neu5Gc-specific antibodies. Such mice developed hepatocellular carcinomas[217]. These studies demonstrate the potential role in cancer development of the sialic acid Neu5Gc and provide an explanation for the epidemiological association between red meat consumption, inflammation and cancer risk.

of α5β1 integrin to fibronectin was greatly reduced as a result of the introduction of a bisecting GlcNAc *N*-glycans on the α5 subunit[137]. Similarly, in MKN45 gastric cancer cells, the overexpression of GnT-III suppresses α3β1 integrin-mediated cell migration on laminin-5, counteracting the GnT-V activity[138]. Overall, GnT-III is described to suppress cancer metastases by at least two major mechanisms: an enhancement in cell–cell adhesion and a downregulation of cell–ECM adhesion[139].

Furthermore, an increased terminal α2,6-sialylation of integrins *N*-glycans can control cancer cell migratory and metastatic potential, interfering with the ligand-binding properties of integrins[101,140]. Analysis of cancer cells that overexpress ST6Gal1 consistently indicates altered adhesion of cells to ECM substrates, such as collagen, fibronectin and laminin in colon cancer[141] and breast cancer cell lines[116].

Additionally, altered *N*-glycosylation of integrins can have an impact on their *cis*-interaction with membrane-associated receptors, including EGFR[142] and the tetraspanin family of proteins, as well as gangliosides in the microdomain. Glycosylation of α3β1 integrin was demonstrated to regulate its association with the tetraspanin CD151, modulating cell spreading and motility[143]. Therefore, changes in the *N*-glycosylation profile of integrins modulate tumour cell motility and migration through interference with the supramolecular complex formation (tumour cell focal adhesions) on the cell surface. In the formation of these focal adhesions, integrins interact with HSPG on the surface of tumour cells[144]. Syndecan-4 is frequently upregulated in a range of cancers[145]; it binds to fibronectin and laminin-5 enhancing the function of β1 integrin during cell spreading[146]. Similarly, syndecan-1 was described to functionally couple with αvβ3 integrin in breast cancer cells, resulting in increased αvβ3-dependent cell spreading and migration[147].

Glycosylation in cancer metabolism and signalling. A key feature of cancer cell metabolism is a shift from oxidative phosphorylation to aerobic glycolysis (the Warburg effect)[148], which is characterized by high rates of glucose uptake to cope with the increased energetic and biosynthetic needs to generate a tumour. Additionally, to help meet increased biosynthetic demands, cancer cells also upregulate glutamine uptake. The abundance of glucose in the cytoplasm of cancer cells not only contributes to increased glycolysis but also increases flux into the metabolic branch pathways, such as the hexosamine biosynthetic pathway (HBP). Approximately 3–5% of the total glucose entering a cell is shunted through this pathway[149]. Therefore, increased glucose and glutamine uptake by cancer cells probably drives increased HBP flux. The end-product of HBP is uridine diphosphate (UDP)-GlcNAc, which is a critical metabolite that is subsequently used for *O*-GlcNAcylation as well as for *O*- and *N*-glycosylation[150]. Given *O*-GlcNAcylation responsiveness to the glucose flux, *O*-GlcNAc can act as a 'nutritional sensor' (REF. 151).

Increased levels of *O*-GlcNAc transferase (OGT) have been found in breast cancer, and knockdown of OGT *in vitro* reduces cancer hyper-*O*-GlcNAcylation and inhibits tumour growth, invasion and metastasis, further indicating that elevated *O*-GlcNAc contributes to cancer progression[152–154]. Moreover, *O*-GlcNAc modulates key protein functions by regulating protein phosphorylation, altering protein degradation, controlling protein localization and mediating transcription[155]. *O*-GlcNAc modifications have been implicated in key molecular events occurring in cancer, such as tumour cell proliferation (by regulating the activities of transcription factor forkhead box protein M1(FoxM1) and cyclin D1, which are both involved in cell cycle progression[154]), cancer cell survival and angiogenesis (through the effect of hyper-*O*-GlcNAcylation (via activation of nuclear factor κB-mediated signalling[153]) and upregulation of VEGFA and matrix metalloproteinases (MMPs)[156], respectively), and cancer cell invasion and metastasis (through *O*-GlcNAc regulation of E-cadherin trafficking and function)[157].

Many oncogene and tumour-suppressor gene products were shown to be modified by *O*-GlcNAc[158]. MYC undergoes *O*-GlcNAcylation at Thr58, which is also a phosphorylation site. In fact, *O*-GlcNAcylation has extensive crosstalk with phosphorylation and serves as a nutrient sensor to modulate signalling, transcription and cytoskeletal functions[158]. Altered phosphorylation events affect GlcNAcylation levels and vice versa. Increased MYC *O*-GlcNAcylation competes with phosphorylation, stabilizing MYC and thus contributing to oncogenesis[159]. This type of interplay also occurs with the p53 tumour-suppressor protein[160].

Similarly to *O*-GlcNAcylation, *N*-glycan branching is nutrient sensitive, with functional consequences for the cancer cell. The degree of *N*-glycan branching modulates the activity and/or signalling and surface retention of many cell surface proteins, including growth factor receptors[97].

Cell surface glycoprotein receptors have different number of *N*-glycan sites. The number of *N*-glycans is defined by the protein sequence of each glycoprotein, and the types of *N*-glycan structures are determined by the Golgi *N*-glycan-processing pathway and metabolite supply to sugar–nucleotide pools[161]. Receptors that stimulate cell proliferation, growth and oncogenesis (such as EGFR, IGF receptor (IGFR), fibroblast growth factor (FGFR) and platelet-derived growth factor (PDGFR)) have more *N*-glycan sites (8–16 Asn-X-Ser/Thr sites, in which X is any amino acid) per 100 amino acids, and longer extracellular domains. Conversely, growth-arrest receptors involved in organogenesis and differentiation (such as TGFβ receptor 1 (TGFβR1) and TGFβR2) have few *N*-glycan sites[161]. Lau *et al.* proposed a mechanism for metabolic regulation of cellular transition between cell proliferation and arrest and/or differentiation that arises from the cooperation of complex *N*-glycan number and the degree of branching structures[161]. Changes in metabolic flux through the HBP affect the stability and retention of receptors at the cell surface by modulating the interaction of branched *N*-glycans with galectin-3 (REFS 162,163). The galectin-3 lattice restricts receptor endocytosis, enhancing the signalling[68,161]. Hence, the more *N*-glycan sites, the more β1,6-branching structures are added, which crosslink with galectins, precluding

Microdomain
A plasma membrane domain containing glycosphingolipids and proteins receptors influencing membrane fluidity, protein assembly and signalling.

O-GlcNAcylation
A covalent addition of *N*-acetylglucosamine (GlcNAc) to Ser or Thr hydroxyl moieties by *O*-GlcNAc transferase on nuclear and cytoplasmic proteins.

Tumour editing
Changes in tumour immunogenicity due to the antitumour response of the immune system, leading to emergence of immune-resistant cancer cell variants.

endocytosis and thereby increasing signalling[161,162]. Mammary carcinoma cells derived from polyomavirus middle T (PyMT) *Mgat5*$^{-/-}$-transgenic mice are less responsive to IGF, EGF, PDGF, FGF and TGFβ compared with *Mgat5*$^{+/+}$ tumour cells, showing reduced galectin-3 binding and internalization of receptors from the cell surface to endosomes[164]. Similarly, human cancer cells with targeted silencing of the *MGAT5* gene also exhibit reduced EGFR signalling[165]. Sensitivity to EGF and TGFβ cytokines was rescued by hexosamine supplementation with UDP-GlcNAc or by GnT-V expression, implying that remodelling of *N*-glycans in tumour cells is sensitive to metabolism[161]. Accordingly, the decrease of galectin lattice interactions induced by the addition of bisecting GlcNAc *N*-glycans counterbalances the highly branched *N*-glycosylation of EGFR and PDGFR, restraining its downstream signalling and in this way retarding mammary tumour progression[166]. GnT-III overexpression reduces the ability of EGF to bind to its receptor, blocking EGFR-mediated ERK phosphorylation and increasing EGFR endocytosis[167]. Increasing intracellular metabolic flux with UDP-GlcNAc promotes a hyperbolic activation profile for high-n receptors (receptors with a high number of *N*-glycan sites (growth receptors)) and a sigmoid or switch-like profile for low-n receptors (receptors with a reduced number of *N*-glycan sites (arrest receptors)), thereby regulating the transition between cell growth and differentiation[161]. Overall, the nutrient flux that regulates complex *N*-glycan biosynthesis coordinates the cellular response of tumour cells determining growth, invasion and drug sensitivity[100]. Interestingly, the presence of branching *N*-glycans on VEGFR2 interacting with galectin-1 underlies an aberrant and compensatory angiogenesis mechanism associated with tumour growth in tumours resistant to anti-VEGF treatment[69].

Gangliosides have been described as important modulators of signal transduction. Ectopic expression or inhibition of specific glycosyltransferases modifying gangliosides regulates RTK signalling. Within glycolipid-enriched microdomains, RTKs can be modulated by glycans, resulting in inhibition of ligand-induced dimerization and autophosphorylation or in activation of receptor signalling without ligand binding. The RTK modulation depends on the glycan structure; monosialogangliosides (such as GM3 and GM1) are considered negative regulators of RTKs, whereas disialogangliosides (such as GD2, GD3, GD1a and GD1b) are considered activators of RTKs[17]. Furthermore, physiopathological changes in cell membrane ganglioside composition have been shown to result in different cellular responses[168]. Several growth factor receptors, including EGFR, FGFR, PDGF, MET and IGFR, are regulated by gangliosides[17,53,169]. RTKs are located in glycolipid-enriched microdomains, and changes in gangliosides modify the molecular composition and the structure of glycolipid-enriched microdomains, leading to modifications in the location and organization of RTKs in the cellular membrane and altered activation[53,169]. Further regulation of specific ganglioside GD3 due to formation of 9-*O*-acetyl GD3 that renders GD3 unable to induce apoptosis has been shown in gliomas[170].

Glycans in tumour immune surveillance

Glycans regulate various aspects of the immune response interfering with tumour editing. Such regulation is mediated by various lectins — such as galectins, C-type lectins and siglecs — that bind glycans and regulate immune processes such as those relevant for pathogen recognition, thereby defining the course of adaptive immune responses[171,172]. Cancer immune surveillance is an important host protection process thought to inhibit carcinogenesis and maintain cellular homeostasis. Transformed cells can be eliminated by immune effector cells, resulting in immune selection of tumour cell variants with decreased immunogenicity and resistance to immune effector cells. Glycan-specific natural and induced antibodies (such as those against GM2, globo H and Le^{y}) can mediate tumour cell killing and tissue destruction by complement-dependent cytotoxicity[173]. In addition, aberrant *O*-glycosylation on the surface of cancer cells can induce antibody-dependent cellular cytotoxicity (ADCC)[174] and may interact with dendritic cell-specific intercellular adhesion molecule-3 grabbing non-integrin 1 (DC-SIGN; also known as CD209)[175] and macrophage galactose-type C-type lectin[176] expressed on denditric cells. Galectins can also modulate the immune and inflammatory responses and might have a key role helping tumours to escape immune surveillance, therefore having diagnostic and prognostic applications[171,177–179].

Targeting altered glycosylation as an immunotherapeutic strategy — for example, with anticancer vaccines that target tumour-associated carbohydrate antigens[180] — provides an appealing option for cancer treatment[92]. Examples include vaccines targeting the mucin-related Tn, STn, and T antigens for suppression of breast cancer, the gangliosides GM2 and GD3 for treatment of melanoma, and the glycosphingolipid globo-H for prostate cancer treatment[181].

Some of these anticancer vaccines can be designed to incorporate only those elements required for a desired immune response[182–184]. Antibodies targeting GD2 disialoganglioside have been tested in numerous clinical trials in neuroblastoma with impressive antitumour effects and survival outcomes[185].

Passive immunotherapy using antibodies directed to glycoform-specific targets expressed in tumour cells can be effective at inducing ADCC[174]. Other studies have shown that ADCC is a key mechanism by which some currently used therapeutic antibodies mediate their antitumour effects. Variations of glycosylation on the heavy chain of the therapeutic antibodies can increase the affinity between the antibody and Fcγ receptor, resulting in increased ADCC[186].

Glycans in cancer diagnosis and treatment

New approaches for cancer early diagnosis, risk prediction and treatment are urgently needed, and glycans can be a source for the development of new non-invasive biomarkers.

Some of the most-common clinically utilized serological biomarkers for cancer diagnosis and monitoring of malignant progression, as well as prognostic biomarkers of disease recurrence, are glycoproteins[3,49]. These

include prominent biomarkers that are widely used in patients with prostate cancer (prostate-specific antigen (PSA))[187], ovarian cancer (carcinoma antigen 125 (CA125; also known as mucin-16 (MUC16)))[188], colon cancer (SLe^a, CA19-9, [3,49] and carcinoembryonic antigen (CEA)[189]), breast cancer (aberrantly glycosylated MUC1 (also known as CA15-3))[190,191] gastric cancer (SLe^a, CA19-9)[3,49] and pancreatic cancer (SLe^a, CA19-9)[192] (TABLE 1). Although all of these serological biomarkers have been shown to have an aberrant glycosylation in cancer[193–195], they have limited application owing to their relative low specificity, precluding their use for screening strategies and diagnostic potential. The reduced specificity and sensitivity of these assays for early detection of cancer has driven a search for novel biomarkers based on the detection and measurement of specific glycoforms of a certain protein that could contribute to the establishment of a biomarker with higher specificity for early detection of cancer or for diagnosis at a precancerous stage. A story of success is that of α-fetoprotein (AFP), a glyco-biomarker used for the detection of liver diseases. AFP is a broadly validated protein for diagnosis of HCC[65;] however, serum levels of AFP do not allow discrimination between HCC and the benign liver diseases. Therefore, an additional tumour marker was proposed, based on a glycosylated form of AFP (the AFP-L3 fraction) that shows a highly significant increase in the fucosylation index in HCC patients in comparison to chronic liver diseases[196]. The fucosylated AFP-L3 fraction was approved by FDA as a marker for early detection of HCC that appears in serum at the stage of liver cirrhosis, just before the onset of HCC, being therefore considered the best approved marker in patients with HCC[65,196]. Other liver-secreted proteins, such as GP73, kininogen and haptoglobin, have been shown to be fucosylated, acting as promising biomarkers for early detection of HCC and disease progression[197].

With the advent of new technologies and new methods for glycan analysis, many examples of aberrant glycans associated with cancer were discovered[198]. The recent application of precise and stable glycogene editing in mammalian cell lines combined with high-throughput mass spectrometry approaches has contributed to the characterization of the *O*-glycoproteome of cancer cells, disclosing new biological information and generating putative disease biomarkers[199,200]. In addition, the newly developed high-throughput platform technologies have further enabled the analysis of large cohorts of samples in an efficient manner[198,201]. An increased concentration of fucosylated haptoglobin occurs in serum of patients with pancreatic cancer compared with that of patients with other types of cancer, such as gastric cancer or CRC, and healthy controls[202]. Recently, STn antigen was found in circulating CD44 in serum from patients with gastric cancer[200]. In addition, STn has been found in plasminogen in serum from patients with intestinal metaplasia and gastric carcinoma[203]. Additional studies showed altered glycosylation (both fucosylation and sialylation) in PSA as a specific biomarker for prostate cancer that is able to distinguish it from benign prostate hyperplasia[187,204]. Therefore, it is likely that targeting glycans in combination with the protein backbone will provide greater diagnostic and prognostic performance, with sufficient sensitivity and specificity for clinical applications.

Additionally, circulating exosomes enriched in certain glycoconjugates have major potential for early detection of cancer. This is the case of proteoglycan glypican 1 (GPC1), which has been shown to identify circulating pancreatic cancer exosomes and allows the early detection of this cancer[205].

Serum antibodies against tumour-associated glycan antigens have been shown to have potential applications as biomarkers for early cancer detection[206]. The detection of aberrant glycosylated MUC1-specific autoantibodies correlates with CRC, predicting this cancer with 95% specificity[207]. However, the low sensitivity of the assay supports the use of it in combination with other markers, suggesting that a combination of antibody signatures may eventually enable a biomarker panel for the early detection of cancer[207]. Furthermore, microarrays of glycopeptides displaying cancer-associated glycans open new avenues for the expansion of glycoconjugates

Table 1 | **Examples of serological markers with clinical applications**

Serological marker	Glycoprotein or glycoform	Cancers	Application in the clinic	Refs
AFP	AFP 'core' fucosylation (AFP-L3)	Hepatocellular carcinoma	Early diagnosis and monitoring	65,196
CA19-9	SLe^a	Biliary, colorectal, gastric and pancreatic	Therapeutic monitoring, recurrence and tumour burden	49,192
CA72-4	STn	Gastric	Monitoring	219
CA15-3	MUC1	Breast	Monitoring	190,191
CA125	MUC16	Ovarian	Monitoring and recurrence	188
CEA	CEA	Colorectal	Monitoring and recurrence	189
PSA	PSA	Prostate	Diagnosis, monitoring and recurrence	187
β-hCG	β-hCG	Gynaecological	Monitoring	220

β-hCG, β-human chorionic gonadotropin; AFP, α-fetoprotein; CA, cancer antigen; CEA, carcinoembryonic antigen; MUC, mucin; PSA, prostate specific antigen; SLe^a, sialyl Lewis a; STn, sialyl Tn.

and glycoforms for further cancer biomarker discovery with potential clinical applications[206].

In summary, the impressive progress in the understanding the role of glycans in cancer in the recent years has contributed to the discovery of glycans as promising biomarkers, highlighting their application in the clinical setting as appealing targets for personalized medicine[180].

Conclusions and perspectives

Glycosylated proteins and other glycoconjugates are major components of cells, defining and modulating several key physiological processes in normal tissues. Genetic, epigenetic, metabolic, inflammatory and environmental mechanisms can lead to modifications of glycosylation that drive several biological processes in cancer. The understanding of the molecular basis underlying these glycan modifications will further contribute to explain cancer cell interactions, extracellular communications (including extracellular vesicles and exosome communication) and cancer immunology. The foreseeable new knowledge in the glycobiology field, with the rapid expansion of novel (glyco)engineered cell and model platforms, which are providing increasing advances in the understanding of how glycosylation modulates biological functions, will allow the development of a relatively unexploited field of drugs based on inhibitors, glycan antagonists and glycan-function modulators. Furthermore, the combination of an increasing amount of data on glycomics and glycoproteomics and the recent advances in genomics, transcriptomics, proteomics and metabolomics will have a major impact on the unravelling of novel targets and strategies for the early diagnosis, prognosis, patient stratification and improved treatment of cancer.

1. Fuster, M. M. & Esko, J. D. The sweet and sour of cancer: glycans as novel therapeutic targets. *Nat. Rev. Cancer* **5**, 526–542 (2005).
2. Hakomori, S. Glycosylation defining cancer malignancy: new wine in an old bottle. *Proc. Natl Acad. Sci. USA* **99**, 10231–10233 (2002).
3. Reis, C. A., Osorio, H., Silva, L., Gomes, C. & David, L. Alterations in glycosylation as biomarkers for cancer detection. *J. Clin. Pathol.* **63**, 322–329 (2010).
4. Taniguchi, N., Hancock, W., Lubman, D. M. & Rudd, P. M. The second golden age of glycomics: from functional glycomics to clinical applications. *J. Proteome Res.* **8**, 425–426 (2009).
5. Pinho, S. S. *et al.* Gastric cancer: adding glycosylation to the equation. *Trends Mol. Med.* **19**, 664–676 (2013).
6. Freeze, H. H. Understanding human glycosylation disorders: biochemistry leads the charge. *J. Biol. Chem.* **288**, 6936–6945 (2013).
This Review describes the genetic and biochemical advances in the diagnosis of several inherited human glycosylation disorders.
7. Ohtsubo, K. & Marth, J. D. Glycosylation in cellular mechanisms of health and disease. *Cell* **126**, 855–867 (2006).
8. Varki, A. *et al.* (eds) *Essentials of Glycobiology* 2nd edn (Cold Spring Harbor Laboratory Press, 2009).
9. Cummings, R. D. The repertoire of glycan determinants in the human glycome. *Mol. Biosyst.* **5**, 1087–1104 (2009).
10. Gabius, H. J., Andre, S., Jimenez-Barbero, J., Romero, A. & Solis, D. From lectin structure to functional glycomics: principles of the sugar code. *Trends Biochem. Sci.* **36**, 298–313 (2011).
11. Moremen, K. W., Tiemeyer, M. & Nairn, A. V. Vertebrate protein glycosylation: diversity, synthesis and function. *Nat. Rev. Mol. Cell Biol.* **13**, 448–462 (2012).
12. Bennett, E. P. *et al.* Control of mucin-type *O*-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. *Glycobiology* **22**, 736–756 (2012).
This article reports on the biological function of the polypeptide GalNAc transferase gene family, the largest glycosyltransferase enzyme family.
13. Clausen, H. & Bennett, E. P. A family of UDP-GalNAc: polypeptide *N*-acetylgalactosaminyl-transferases control the initiation of mucin-type *O*-linked glycosylation. *Glycobiology* **6**, 635–646 (1996).
14. Brockhausen, I., Yang, J., Lehotay, M., Ogata, S. & Itzkowitz, S. Pathways of mucin *O*-glycosylation in normal and malignant rat colonic epithelial cells reveal a mechanism for cancer-associated sialyl-Tn antigen expression. *Biol. Chem.* **382**, 219–232 (2001).
This Review describes the pathways of mucin-type *O*-glycosylation.
15. Ma, J. & Hart, G. W. *O*-GlcNAc profiling: from proteins to proteomes. *Clin. Proteomics* **11**, 8 (2014).
16. Luther, K. B. & Haltiwanger, R. S. Role of unusual *O*-glycans in intercellular signaling. *Int. J. Biochem. Cell Biol.* **41**, 1011–1024 (2009).
17. Julien, S., Bobowski, M., Steenackers, A., Le Bourhis, X. & Delannoy, P. How do gangliosides regulate RTKs signaling? *Cells* **2**, 751–767 (2013).
18. Ladenson, R. P., Schwartz, S. O. & Ivy, A. C. Incidence of the blood groups and the secretor factor in patients with pernicious anemia and stomach carcinoma. *Am. J. Med. Sci.* **217**, 194–197 (1949).
19. Hakomori, S. I. & Murakami, W. T. Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines. *Proc. Natl Acad. Sci. USA* **59**, 254–261 (1968).
20. Feizi, T. Carbohydrate antigens in human cancer. *Cancer Surv.* **4**, 245–269 (1985).
21. Holmes, E. H., Ostrander, G. K., Clausen, H. & Graem, N. Oncofetal expression of Lex carbohydrate antigens in human colonic adenocarcinomas. Regulation through type 2 core chain synthesis rather than fucosylation. *J. Biol. Chem.* **262**, 11331–11338 (1987).
22. Hakomori, S. & Kannagi, R. Glycosphingolipids as tumor-associated and differentiation markers. *J. Natl Cancer Inst.* **71**, 231–251 (1983).
23. Marcos, N. T. *et al.* ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. *Front. Biosci. (Elite Ed.)* **3**, 1443–1455 (2011).
24. Julien, S. *et al.* ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their *O*-glycosylation pattern and enhances their tumourigenicity. *Glycobiology* **16**, 54–64 (2006).
25. Kannagi, R., Yin, J., Miyazaki, K. & Izawa, M. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants—Hakomori's concepts revisited. *Biochim. Biophys. Acta* **1780**, 525–531 (2008).
This Review describes the incomplete synthesis and neo-synthesis processes as two major concepts for cancer-associated alterations of cell-surface carbohydrate determinants.
26. Buckhaults, P., Chen, L., Fregien, N. & Pierce, M. Transcriptional regulation of *N*-acetylglucosaminyltransferase V by the *src* oncogene. *J. Biol. Chem.* **272**, 19575–19581 (1997).
27. Hatano, K., Miyamoto, Y., Nonomura, N. & Kaneda, Y. Expression of gangliosides, GD1a, and sialyl paragloboside is regulated by NF-κB-dependent transcriptional control of α2,3-sialyltransferase I, II, and VI in human castration-resistant prostate cancer cells. *Int. J. Cancer* **129**, 1838–1847 (2011).
28. Pinho, S. S. *et al.* Loss and recovery of Mgat3 and GnT-III Mediated E-cadherin *N*-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions. *PLoS ONE* **7**, e33191 (2012).
29. Schietinger, A. *et al.* A mutant chaperone converts a wild-type protein into a tumor-specific antigen. *Science* **314**, 304–308 (2006).
30. Aryal, R. P., Ju, T. & Cummings, R. D. The endoplasmic reticulum chaperone Cosmc directly promotes *in vitro* folding of T-synthase. *J. Biol. Chem.* **285**, 2456–2462 (2010).
31. Kakugawa, Y. *et al.* Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. *Proc. Natl Acad. Sci. USA* **99**, 10718–10723 (2002).
32. Kumamoto, K. *et al.* Increased expression of UDP-galactose transporter messenger RNA in human colon cancer tissues and its implication in synthesis of Thomsen-Friedenreich antigen and sialyl Lewis A/X determinants. *Cancer Res.* **61**, 4620–4627 (2001).
33. Kellokumpu, S., Sormunen, R. & Kellokumpu, I. Abnormal glycosylation and altered Golgi structure in colorectal cancer: dependence on intra-Golgi pH. *FEBS Lett.* **516**, 217–224 (2002).
34. Gill, D. J., Chia, J., Senewiratne, J. & Bard, F. Regulation of *O*-glycosylation through Golgi-to-ER relocation of initiation enzymes. *J. Cell Biol.* **189**, 843–858 (2010).
35. Brockhausen, I. Mucin-type *O*-glycans in human colon and breast cancer: glycodynamics and functions. *EMBO Rep.* **7**, 599–604 (2006).
36. Marcos, N. T. *et al.* Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. *Cancer Res.* **64**, 7050–7057 (2004).
This study demonstrates that ST6GalNAc-I is responsible for the biosynthesis of the STn antigen in gastric cancer cells.
37. Roth, J., Wang, Y., Eckhardt, A. E. & Hill, R. L. Subcellular localization of the UDP-*N*-acetyl-D-galactosamine: polypeptide *N*-acetylgalactosaminylt ransferase-mediated *O*-glycosylation reaction in the submaxillary gland. *Proc. Natl Acad. Sci. USA* **91**, 8935–8939 (1994).
38. Sewell, R. *et al.* The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn *O*-glycan in human breast cancer. *J. Biol. Chem.* **281**, 3586–3594 (2006).
39. Christiansen, M. N. *et al.* Cell surface protein glycosylation in cancer. *Proteomics* **14**, 525–546 (2014).
40. Arnold, J. N., Saldova, R., Hamid, U. M. & Rudd, P. M. Evaluation of the serum *N*-linked glycome for the diagnosis of cancer and chronic inflammation. *Proteomics* **8**, 3284–3293 (2008).
41. Kim, Y. J. & Varki, A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. *Glycoconj. J.* **14**, 569–576 (1997).
42. Dall'Olio, F. & Chiricolo, M. Sialyltransferases in cancer. *Glycoconj. J.* **18**, 841–850 (2001).
43. Lise, M. *et al.* Clinical correlations of α2,6-sialyltransferase expression in colorectal cancer patients. *Hybridoma* **19**, 281–286 (2000).
44. Amado, M., Carneiro, F., Seixas, M., Clausen, H. & Sobrinho-Simoes, M. Dimeric sialyl-Le^x expression in gastric carcinoma correlates with venous invasion and poor outcome. *Gastroenterology* **114**, 462–470 (1998).
45. Baldus, S. E. *et al.* Histopathological subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: Sialosyl-Lewis^a, Sialosyl-Lewis^x and sialosyl-Tn. *Tumour Biol.* **19**, 445–453 (1998).

46. Rosen, S. D. & Bertozzi, C. R. The selectins and their ligands. *Curr. Opin. Cell Biol.* **6**, 663–673 (1994).
47. Nakamori, S. *et al.* Increased expression of sialyl Lewis^x antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. *Cancer Res.* **53**, 3632–3637 (1993).
48. Borsig, L. *et al.* Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. *Proc. Natl Acad. Sci. USA* **98**, 3352–3357 (2001).
49. Locker, G. Y. *et al.* ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J. Clin. Oncol.* **24**, 5313–5327 (2006).
50. Marrelli, D. *et al.* Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer. *J. Surg. Oncol.* **78**, 253–258 (2001).
51. Tanaka, F. *et al.* Prognostic significance of polysialic acid expression in resected non-small cell lung cancer. *Cancer Res.* **61**, 1666–1670 (2001).
52. Falconer, R. A., Errington, R. J., Shnyder, S. D., Smith, P. J. & Patterson, L. H. Polysialyltransferase: a new target in metastatic cancer. *Curr. Cancer Drug Targets* **12**, 925–939 (2012).
53. Todeschini, A. R., Dos Santos, J. N., Handa, K. & Hakomori, S. I. Ganglioside GM2-tetraspanin CD82 complex inhibits met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse. *J. Biol. Chem.* **282**, 8123–8133 (2007).
54. Carvalho, A. S. *et al.* Differential expression of α-2,3-sialyltransferases and α-1,3/4-fucosyltransferases regulates the levels of sialyl Lewis a and sialyl Lewis x in gastrointestinal carcinoma cells. *Int. J. Biochem. Cell Biol.* **42**, 80–89 (2010).
55. de Vries, T., Knegtel, R. M., Holmes, E. H. & Macher, B. A. Fucosyltransferases: structure/function studies. *Glycobiology* **11**, 119R–128R (2001).
56. Hiraiwa, N. *et al.* Transactivation of the fucosyltransferase VII gene by human T-cell leukemia virus type 1 Tax through a variant cAMP-responsive element. *Blood* **101**, 3615–3621 (2003).
57. Matsuura, N. *et al.* Gene expression of fucosyl- and sialyl-transferases which synthesize sialyl Lewis^x, the carbohydrate ligands for E-selectin, in human breast cancer. *Int. J. Oncol.* **12**, 1157–1164 (1998).
58. Holmes, E. H., Hakomori, S. & Ostrander, G. K. Synthesis of type 1 and 2 lacto series glycolipid antigens in human colonic adenocarcinoma and derived cell lines is due to activation of a normally unexpressed β1→3*N*-acetylglucosaminyltransferase. *J. Biol. Chem.* **262**, 15649–15658 (1987).
59. Marcos, N. T. *et al. Helicobacter pylori* induces β3GnT5 in human gastric cell lines, modulating expression of the SabA ligand sialyl-Lewis x. *J. Clin. Invest.* **118**, 2325–2336 (2008).
60. Magalhaes, A. *et al. Helicobacter pylori* chronic infection and mucosal inflammation switches the human gastric glycosylation pathways. *Biochim. Biophys. Acta* **1852**, 1928–1939 (2015).
61. Trinchera, M. *et al.* The biosynthesis of the selectin-ligand sialyl Lewis x in colorectal cancer tissues is regulated by fucosyltransferase VI and can be inhibited by an RNA interference-based approach. *Int. J. Biochem. Cell Biol.* **43**, 130–139 (2011).
62. Liu, Y. C. *et al.* Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. *Proc. Natl Acad. Sci. USA* **108**, 11332–11337 (2011).
63. Potapenko, I. O. *et al.* Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. *Mol. Oncol.* **4**, 98–118 (2010).
64. Hutchinson, W. L., Du, M. Q., Johnson, P. J. & Williams, R. Fucosyltransferases: differential plasma and tissue alterations in hepatocellular carcinoma and cirrhosis. *Hepatology* **13**, 683–688 (1991).
65. Sato, Y. *et al.* Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. *N. Engl. J. Med.* **328**, 1802–1806 (1993).
This study revealed the capacity of α-fetoprotein L3 and α-fetoprotein P4 + P5 in serum to act as predictive markers to differentiate HCC from cirrhosis.
66. Takahashi, M., Kuroki, Y., Ohtsubo, K. & Taniguchi, N. Core fucose and bisecting GlcNAc, the direct modifiers of the *N*-glycan core: their functions and target proteins. *Carbohydr. Res.* **344**, 1387–1390 (2009).
67. Dennis, J. W., Laferte, S., Waghorne, C., Breitman, M. L. & Kerbel, R. S. Beta 1–6 branching of Asn-linked oligosaccharides is directly associated with metastasis. *Science* **236**, 582–585 (1987).
This study reported that increased expression of β1–6-linked branching oligosaccharide structures is directly related to the metastatic potential of the cells.
68. Di Lella, S. *et al.* When galectins recognize glycans: from biochemistry to physiology and back again. *Biochemistry* **50**, 7842–7857 (2011).
69. Croci, D. O. *et al.* Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. *Cell* **156**, 744–758 (2014).
This article describes a glycosylation-dependent pathway that preserves angiogenesis in anti-VEGF refractory tumours.
70. Demetriou, M., Nabi, I. R., Coppolino, M., Dedhar, S. & Dennis, J. W. Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. *J. Cell Biol.* **130**, 383–392 (1995).
71. Seberger, P. J. & Chaney, W. G. Control of metastasis by Asn-linked, β1–6 branched oligosaccharides in mouse mammary cancer cells. *Glycobiology* **9**, 235–241 (1999).
72. Guo, H. B. *et al.* Specific posttranslational modification regulates early events in mammary carcinoma formation. *Proc. Natl Acad. Sci. USA* **107**, 21116–21121 (2010).
73. Granovsky, M. *et al.* Suppression of tumor growth and metastasis in Mgat5-deficient mice. *Nat. Med.* **6**, 306–312 (2000).
This study reports the establishment of mice deficient in *Mgat5* by targeted gene mutation. Mammary tumour growth and metastases induced by the polyomavirus middle T oncogene were considerably suppressed in *Mgat5*$^{-/-}$ mice compared with in transgenic littermates expressing *Mgat5*.
74. Guo, H., Nagy, T. & Pierce, M. Post-translational glycoprotein modifications regulate colon cancer stem cells and colon adenoma progression in Apc$^{min/+}$ mice through altered Wnt receptor signaling. *J. Biol. Chem.* **289**, 31534–31549 (2014).
75. Yoshimura, M., Nishikawa, A., Ihara, Y., Taniguchi, S. & Taniguchi, N. Suppression of lung metastasis of B16 mouse melanoma by *N*-acetylglucosaminyltransferase III gene transfection. *Proc. Natl Acad. Sci. USA* **92**, 8754–8758 (1995).
This article provides the first demonstration of the tumour-suppressive role of GnT-III.
76. Zhao, Y. *et al.* Branched *N*-glycans regulate the biological functions of integrins and cadherins. *FEBS J.* **275**, 1939–1948 (2008).
77. Kudelka, M. R., Ju, T., Heimburg-Molinaro, J. & Cummings, R. D. Simple sugars to complex disease—mucin-type *O*-glycans in cancer. *Adv. Cancer Res.* **126**, 53–135 (2015).
78. Berois, N. *et al. GALNT9* gene expression is a prognostic marker in neuroblastoma patients. *Clin. Chem.* **59**, 225–233 (2013).
79. Gomes, J. *et al.* Expression of UDP-*N*-acetyl-D-galactosamine: polypeptide *N*-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma. *J. Histochem. Cytochem.* **57**, 79–86 (2009).
80. Gill, D. J. *et al.* Initiation of GalNAc-type *O*-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness. *Proc. Natl Acad. Sci. USA* **110**, E3152–E3161 (2013).
81. Dalziel, M. *et al.* The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine *O*-glycan structure and expression of a tumor-associated epitope on MUC1. *J. Biol. Chem.* **276**, 11007–11015 (2001).
82. Reis, C. A., David, L., Seixas, M., Burchell, J. & Sobrinho-Simoes, M. Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. *Int. J. Cancer* **79**, 402–410 (1998).
83. Itzkowitz, S. *et al.* Expression of Tn, sialosyl Tn, and T antigens in human pancreas. *Gastroenterology* **100**, 1691–1700 (1991).
84. Radhakrishnan, P. *et al.* Immature truncated *O*-glycophenotype of cancer directly induces oncogenic features. *Proc. Natl Acad. Sci. USA* **111**, E4066–E4075 (2014).
85. Pinho, S. *et al.* Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. *Cancer Lett.* **249**, 157–170 (2007).
86. David, L., Nesland, J. M., Clausen, H., Carneiro, F. & Sobrinho-Simoes, M. Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carcinomas and metastases. *APMIS Suppl.* **27**, 162–172 (1992).
87. Dall'Olio, F., Malagolini, N., Trinchera, M. & Chiricolo, M. Mechanisms of cancer-associated glycosylation changes. *Front. Biosci. (Landmark Ed.)* **17**, 670–699 (2012).
88. Ferreira, J. A. *et al.* Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. *Mol. Oncol.* **7**, 719–731 (2013).
89. Ricardo, S. *et al.* Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours. *Mol. Oncol.* **9**, 503–512 (2015).
90. Ju, T. & Cummings, R. D. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 β3-galactosyltransferase. *Proc. Natl Acad. Sci. USA* **99**, 16613–16618 (2002).
This study describes the role of the molecular chaperone C1GALT1C1 for activity of the core 1 β3-GalT.
91. Ju, T. *et al.* Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. *Cancer Res.* **68**, 1636–1646 (2008).
92. Julien, S. *et al.* Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. *Br. J. Cancer* **100**, 1746–1754 (2009).
93. Sandmaier, B. M. *et al.* Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. *J. Immunother.* **22**, 54–66 (1999).
94. Pinho, S. S. *et al.* E-cadherin and adherens-junctions stability in gastric carcinoma: functional implications of glycosyltransferases involving *N*-glycan branching biosynthesis, *N*-acetylglucosaminyltransferases III and V. *Biochim. Biophys. Acta* **1830**, 2690–2700 (2013).
This article reports the biological significance of GnT-III and GnT-V in the modulation of E-cadherin-mediated cell–cell adhesion in cancer.
95. Pinho, S. S. *et al.* The role of *N*-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. *Hum. Mol. Genet.* **18**, 2599–2608 (2009).
96. Takeuchi, H. & Haltiwanger, R. S. Significance of glycosylation in Notch signaling. *Biochem. Biophys. Res. Commun.* **453**, 235–242 (2014).
97. Boscher, C., Dennis, J. W. & Nabi, I. R. Glycosylation, galectins and cellular signaling. *Curr. Opin. Cell Biol.* **23**, 383–392 (2011).
98. de-Freitas-Junior, J. C. *et al.* Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc *N*-glycans modulation. an interplay with E-cadherin. *PLoS ONE* **8**, e81579 (2013).
99. Gomes, C. *et al.* Expression of ST3GAL4 leads to SLe^x expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. *PLoS ONE* **8**, e66737 (2013).
100. Dennis, J. W., Nabi, I. R. & Demetriou, M. Metabolism, cell surface organization, and disease. *Cell* **139**, 1229–1241 (2009).
101. Bassaganas, S. *et al.* Pancreatic cancer cell glycosylation regulates cell adhesion and invasion through the modulation of α2β1 integrin and E-cadherin function. *PLoS ONE* **9**, e98595 (2014).
102. Helenius, A. & Aebi, M. Intracellular functions of *N*-linked glycans. *Science* **291**, 2364–2369 (2001).
103. Pinho, S. S. *et al.* Modulation of E-cadherin function and dysfunction by *N*-glycosylation. *Cell. Mol. Life Sci.* **68**, 1011–1020 (2011).
104. Paredes, J. *et al.* Epithelial E- and P-cadherins: role and clinical significance in cancer. *Biochim. Biophys. Acta* **1826**, 297–311 (2012).
105. Liwosz, A., Lei, T. & Kukuruzinska, M. A. *N*-glycosylation affects the molecular organization and stability of E-cadherin junctions. *J. Biol. Chem.* **281**, 23138–23149 (2006).
106. Guo, H. B., Lee, I., Kamar, M. & Pierce, M. *N*-acetylglucosaminyltransferase V expression levels regulate cadherin-associated homotypic cell–cell adhesion and intracellular signaling pathways. *J. Biol. Chem.* **278**, 52412–52424 (2003).
107. Ihara, S. *et al.* Prometastatic effect of *N*-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding β1–6 GlcNAc branching. *J. Biol. Chem.* **277**, 16960–16967 (2002).

108. Carvalho, S. *et al.* Preventing E-cadherin aberrant *N*-glycosylation at Asn-554 improves its critical function in gastric cancer. *Oncogene* http://dx.doi.org/10.1038/onc.2015.225 (2015).
109. Yoshimura, M., Ihara, Y., Matsuzawa, Y. & Taniguchi, N. Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis. *J. Biol. Chem.* **271**, 13811–13815 (1996).
110. Kitada, T. *et al.* The addition of bisecting *N*-acetylglucosamine residues to E-cadherin down-regulates the tyrosine phosphorylation of beta-catenin. *J. Biol. Chem.* **276**, 475–480 (2001).
111. Xu, Q. *et al.* Roles of *N*-acetylglucosaminyltransferase III in epithelial-to-mesenchymal transition induced by transforming growth factor β1 (TGF-β1) in epithelial cell lines. *J. Biol. Chem.* **287**, 16563–16574 (2012).
112. Gu, J. *et al.* A mutual regulation between cell-cell adhesion and *N*-glycosylation: implication of the bisecting GlcNAc for biological functions. *J. Proteome Res.* **8**, 431–435 (2009).
113. Dennis, J. W., Granovsky, M. & Warren, C. E. Glycoprotein glycosylation and cancer progression. *Biochim. Biophys. Acta* **1473**, 21–34 (1999).
114. Pinho, S. S., Reis, C. A., Gartner, F. & Alpaugh, M. L. Molecular plasticity of E-cadherin and sialyl lewis x expression, in two comparative models of mammary tumorigenesis. *PLoS ONE* **4**, e6636 (2009).
115. Seidenfaden, R., Krauter, A., Schertzinger, F., Gerardy-Schahn, R. & Hildebrandt, H. Polysialic acid directs tumor cell growth by controlling heterophilic neural cell adhesion molecule interactions. *Mol. Cell. Biol.* **23**, 5908–5918 (2003).
This study demonstrates the role of polysialic acid on neural cell adhesion molecule in cancer cells.
116. Lin, S., Kemmner, W., Grigull, S. & Schlag, P. M. Cell surface α2,6 sialylation affects adhesion of breast carcinoma cells. *Exp. Cell Res.* **276**, 101–110 (2002).
117. Tamura, F. *et al.* RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells. *Gastric Cancer* http://dx.doi.org/10.1007/s10120-014-0454-z (2014).
118. Kim, S. H., Turnbull, J. & Guimond, S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. *J. Endocrinol.* **209**, 139–151 (2011).
119. Sarrazin, S., Lamanna, W. C. & Esko, J. D. Heparan sulfate proteoglycans. *Cold Spring Harb. Perspect. Biol.* **3**, a004952 (2011).
120. Wade, A. *et al.* Proteoglycans and their roles in brain cancer. *FEBS J.* **280**, 2399–2417 (2013).
121. Cecchi, F. *et al.* Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. *Cancer Cell* **22**, 250–262 (2012).
122. Tan, K. W. *et al.* Neutrophils contribute to inflammatory lymphangiogenesis by increasing VEGF-A bioavailability and secreting VEGF-D. *Blood* **122**, 3666–3677 (2013).
123. Gunthert, U. *et al.* A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. *Cell* **65**, 13–24 (1991).
124. da Cunha, C. B. *et al. De novo* expression of CD44 variants in sporadic and hereditary gastric cancer. *Lab. Invest.* **90**, 1604–1614 (2010).
125. English, N. M., Lesley, J. F. & Hyman, R. Site-specific de-*N*-glycosylation of CD44 can activate hyaluronan binding, and CD44 activation states show distinct threshold densities for hyaluronan binding. *Cancer Res.* **58**, 3736–3742 (1998).
126. Katoh, S., Zheng, Z., Oritani, K., Shimozato, T. & Kincade, P. W. Glycosylation of CD44 negatively regulates its recognition of hyaluronan. *J. Exp. Med.* **182**, 419–429 (1995).
127. Goupille, C., Hallouin, F., Meflah, K. & Le Pendu, J. Increase of rat colon carcinoma cells tumorigenicity by α(1–2) fucosyltransferase gene transfection. *Glycobiology* **7**, 221–229 (1997).
128. Wolff, E. A. *et al.* Generation of artificial proteoglycans containing glycosaminoglycan-modified CD44. Demonstration of the interaction between rantes and chondroitin sulfate. *J. Biol. Chem.* **274**, 2518–2524 (1999).
129. Roucourt, B., Meeussen, S., Bao, J., Zimmermann, P. & David, G. Heparanase activates the syndecan-syntenin-ALIX exosome pathway. *Cell Res.* **25**, 412–428 (2015).
130. Bharadwaj, A. G. *et al.* Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. *Am. J. Pathol.* **174**, 1027–1036 (2009).
131. Paszek, M. J. *et al.* The cancer glycocalyx mechanically primes integrin-mediated growth and survival. *Nature* **511**, 319–325 (2014).
132. Liotta, L. A. Tumor invasion and metastases—role of the extracellular matrix: Rhoads Memorial Award lecture. *Cancer Res.* **46**, 1–7 (1986).
133. Jin, H. & Varner, J. Integrins: roles in cancer development and as treatment targets. *Br. J. Cancer* **90**, 561–565 (2004).
134. Asada, M., Furukawa, K., Segawa, K., Endo, T. & Kobata, A. Increased expression of highly branched *N*-glycans at cell surface is correlated with the malignant phenotypes of mouse tumor cells. *Cancer Res.* **57**, 1073–1080 (1997).
135. Guo, H. B., Lee, I., Kamar, M., Akiyama, S. K. & Pierce, M. Aberrant *N*-glycosylation of β_1 integrin causes reduced $\alpha_5\beta_1$ integrin clustering and stimulates cell migration. *Cancer Res.* **62**, 6837–6845 (2002).
136. Pochec, E. *et al.* Expression of integrins α3β1 and α5β1 and GlcNAc β1,6 glycan branching influences metastatic melanoma cell migration on fibronectin. *Eur. J. Cell Biol.* **92**, 355–362 (2013).
137. Isaji, T. *et al.* Introduction of bisecting GlcNAc into integrin $\alpha_5\beta_1$ reduces ligand binding and down-regulates cell adhesion and cell migration. *J. Biol. Chem.* **279**, 19747–19754 (2004).
138. Zhao, Y. *et al. N*-acetylglucosaminyltransferase III antagonizes the effect of *N*-acetylglucosaminyltransferase V on α3β1 integrin-mediated cell migration. *J. Biol. Chem.* **281**, 32122–32130 (2006).
139. Gu, J. & Taniguchi, N. Regulation of integrin functions by *N*-glycans. *Glycoconj. J.* **21**, 9–15 (2004).
140. Dennis, J., Waller, C., Timpl, R. & Schirrmacher, V. Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin. *Nature* **300**, 274–276 (1982).
141. Seales, E. C. *et al.* Hypersialylation of β_1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. *Cancer Res.* **65**, 4645–4652 (2005).
142. Kariya, Y., Kawamura, C., Tabei, T. & Gu, J. Bisecting GlcNAc residues on laminin-332 down-regulate galectin-3-dependent keratinocyte motility. *J. Biol. Chem.* **285**, 3330–3340 (2010).
143. Ranjan, A., Bane, S. M. & Kalraiya, R. D. Glycosylation of the laminin receptor (α3β1) regulates its association with tetraspanin CD151: impact on cell spreading, motility, degradation and invasion of basement membrane by tumor cells. *Exp. Cell Res.* **322**, 249–264 (2014).
144. Vlodavsky, I. & Friedmann, Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. *J. Clin. Invest.* **108**, 341–347 (2001).
145. Lendorf, M. E., Manon-Jensen, T., Kronqvist, P., Multhaupt, H. A. & Couchman, J. R. Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. *J. Histochem. Cytochem.* **59**, 615–629 (2011).
146. Saoncella, S. *et al.* Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. *Proc. Natl Acad. Sci. USA* **96**, 2805–2810 (1999).
This article describes how a proteoglycan cooperates with integrins interfering with focal adhesions and actin stress fibres.
147. Beauvais, D. M., Burbach, B. J. & Rapraeger, A. C. The syndecan-1 ectodomain regulates $\alpha_v\beta_3$ integrin activity in human mammary carcinoma cells. *J. Cell Biol.* **167**, 171–181 (2004).
148. Warburg, O. On the origin of cancer cells. *Science* **123**, 309–314 (1956).
149. Marshall, S., Bacote, V. & Traxinger, R. R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. *J. Biol. Chem.* **266**, 4706–4712 (1991).
150. Wells, L., Vosseller, K. & Hart, G. W. Glycosylation of nucleocytoplasmic proteins: signal transduction and *O*-GlcNAc. *Science* **291**, 2376–2378 (2001).
151. Slawson, C., Copeland, R. J. & Hart, G. W. *O*-GlcNAc signaling: a metabolic link between diabetes and cancer? *Trends Biochem. Sci.* **35**, 547–555 (2010).
152. Ferrer, C. M. *et al. O*-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. *Mol. Cell* **54**, 820–831 (2014).
153. Ma, Z. & Vosseller, K. Cancer metabolism and elevated *O*-GlcNAc in oncogenic signaling. *J. Biol. Chem.* **289**, 34457–34465 (2014).
154. Caldwell, S. A. *et al.* Nutrient sensor *O*-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. *Oncogene* **29**, 2831–2842 (2010).
155. Zachara, N. E. & Hart, G. W. Cell signaling, the essential role of *O*-GlcNAc! *Biochim. Biophys. Acta* **1761**, 599–617 (2006).
156. Lynch, T. P. *et al.* Critical role of *O*-linked β-*N*-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. *J. Biol. Chem.* **287**, 11070–11081 (2012).
157. Zhu, W., Leber, B. & Andrews, D. W. Cytoplasmic *O*-glycosylation prevents cell surface transport of E-cadherin during apoptosis. *EMBO J.* **20**, 5999–6007 (2001).
158. Hart, G. W., Slawson, C., Ramirez-Correa, G. & Lagerlof, O. Cross talk between *O*-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. *Annu. Rev. Biochem.* **80**, 825–858 (2011).
159. Itkonen, H. M. *et al. O*-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. *Cancer Res.* **73**, 5277–5287 (2013).
160. Yang, W. H. *et al.* Modification of p53 with *O*-linked *N*-acetylglucosamine regulates p53 activity and stability. *Nat. Cell Biol.* **8**, 1074–1083 (2006).
161. Lau, K. S. *et al.* Complex *N*-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. *Cell* **129**, 123–134 (2007).
162. Stanley, P. A method to the madness of *N*-glycan complexity? *Cell* **129**, 27–29 (2007).
163. Taniguchi, N. A sugar-coated switch for cellular growth and arrest. *Nat. Chem. Biol.* **3**, 307–309 (2007).
164. Partridge, E. A. *et al.* Regulation of cytokine receptors by Golgi *N*-glycan processing and endocytosis. *Science* **306**, 120–124 (2004).
165. Guo, H. B., Johnson, H., Randolph, M., Lee, I. & Pierce, M. Knockdown of GnT-Va expression inhibits ligand-induced downregulation of the epidermal growth factor receptor and intracellular signaling by inhibiting receptor endocytosis. *Glycobiology* **19**, 547–559 (2009).
166. Song, Y., Aglipay, J. A., Bernstein, J. D., Goswami, S. & Stanley, P. The bisecting GlcNAc on *N*-glycans inhibits growth factor signaling and retards mammary tumor progression. *Cancer Res.* **70**, 3361–3371 (2010).
167. Sato, Y. *et al.* Overexpression of *N*-acetylglucosaminyltransferase III enhances the epidermal growth factor-induced phosphorylation of ERK in HeLaS3 cells by up-regulation of the internalization rate of the receptors. *J. Biol. Chem.* **276**, 11956–11962 (2001).
168. Bremer, E. G. & Hakomori, S. Gangliosides as receptor modulators. *Adv. Exp. Med. Biol.* **174**, 381–394 (1984).
169. Park, S. Y., Yoon, S. J., Freire-de-Lima, L., Kim, J. H. & Hakomori, S. I. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells. *Carbohydr. Res.* **344**, 1479–1486 (2009).
170. Birks, S. M. *et al.* Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma. *Neuro Oncol.* **13**, 950–960 (2011).
171. Rabinovich, G. A. & Toscano, M. A. Turning 'sweet' on immunity: galectin–glycan interactions in immune tolerance and inflammation. *Nat. Rev. Immunol.* **9**, 338–352 (2009).
172. Macauley, M. S., Crocker, P. R. & Paulson, J. C. Siglec-mediated regulation of immune cell function in disease. *Nat. Rev. Immunol.* **14**, 653–666 (2014).
173. Ragupathi, G. *et al.* Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. *J. Immunol.* **174**, 5706–5712 (2005).
174. Lavrsen, K. *et al.* Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. *Glycoconj. J.* **30**, 227–236 (2013).
175. Samsen, A. *et al.* DC-SIGN and SRCL bind glycans of carcinoembryonic antigen (CEA) and CEA-related cell adhesion molecule 1 (CEACAM1): recombinant human glycan-binding receptors as analytical tools. *Eur. J. Cell Biol.* **89**, 87–94 (2010).
176. Saeland, E. *et al.* The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. *Cancer Immunol. Immunother.* **56**, 1225–1236 (2007).

177. Laubli, H. *et al.* Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. *J. Biol. Chem.* **289**, 33481–33491 (2014).
178. Liu, F. T. & Rabinovich, G. A. Galectins as modulators of tumour progression. *Nat. Rev. Cancer* **5**, 29–41 (2005).
179. Thijssen, V. L., Heusschen, R., Caers, J. & Griffioen, A. W. Galectin expression in cancer diagnosis and prognosis: a systematic review. *Biochim. Biophys. Acta* **1855**, 235–247 (2015).
180. Dalziel, M., Crispin, M., Scanlan, C. N., Zitzmann, N. & Dwek, R. A. Emerging principles for the therapeutic exploitation of glycosylation. *Science* **343**, 1235681 (2014).
Addresses the potential of glycans to be an important source for the development of novel targeted therapeutic strategies.
181. Slovin, S. F. *et al.* Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. *Proc. Natl Acad. Sci. USA* **96**, 5710–5715 (1999).
182. Buskas, T., Thompson, P. & Boons, G. J. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. *Chem Commun.* **2009**, 5335–5349 (2009).
183. Li, M., Song, L. & Qin, X. Glycan changes: cancer metastasis and anti-cancer vaccines. *J. Biosci.* **35**, 665–673 (2010).
184. Beatson, R. E., Taylor-Papadimitriou, J. & Burchell, J. M. MUC1 immunotherapy. *Immunotherapy* **2**, 305–327 (2010).
185. Mackall, C. L., Merchant, M. S. & Fry, T. J. Immune-based therapies for childhood cancer. *Nat. Rev. Clin. Oncol.* **11**, 693–703 (2014).
186. Liu, S. D. *et al.* Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC. *Cancer Immunol. Res.* **3**, 173–183 (2015).
187. Gilgunn, S., Conroy, P. J., Saldova, R., Rudd, P. M. & O'Kennedy, R. J. Aberrant PSA glycosylation — a sweet predictor of prostate cancer. *Nat. Rev. Urol.* **10**, 99–107 (2013).
Describes the potential of altered PSA-glycosylation patterns to be used as a reliable diagnostic tool in discriminating between significant and insignificant prostate cancers.
188. Zurawski, V. R. Jr, Orjaseter, H., Andersen, A. & Jellum, E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. *Int. J. Cancer* **42**, 677–680 (1988).
189. Goldstein, M. J. & Mitchell, E. P. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. *Cancer Invest.* **23**, 338–351 (2005).
190. Ebeling, F. G. *et al.* Serum CEA and CA 15–13 as prognostic factors in primary breast cancer. *Br. J. Cancer* **86**, 1217–1222 (2002).
191. Kumpulainen, E. J., Keskikuru, R. J. & Johansson, R. T. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. *Breast Cancer Res. Treat.* **76**, 95–102 (2002).
192. Safi, F., Schlosser, W., Kolb, G. & Beger, H. G. Diagnostic value of CA 19–19 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. *J. Gastrointest. Surg.* **1**, 106–112 (1997).
193. Fukushima, K., Satoh, T., Baba, S. & Yamashita, K. α1,2-fucosylated and β-*N*-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. *Glycobiology* **20**, 452–460 (2010).
194. Jankovic, M. M. & Milutinovic, B. S. Glycoforms of CA125 antigen as a possible cancer marker. *Cancer Biomark.* **4**, 35–42 (2008).
195. Saeland, E. *et al.* Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. *Int. J. Cancer* **131**, 117–128 (2012).
196. Noda, K. *et al.* Gene expression of α1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of α-fetoprotein. *Hepatology* **28**, 944–952 (1998).
197. Wang, M. *et al.* Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. *Cancer Epidemiol. Biomarkers Prev.* **18**, 1914–1921 (2009).
198. Adamczyk, B., Tharmalingam, T. & Rudd, P. M. Glycans as cancer biomarkers. *Biochim. Biophys. Acta* **1820**, 1347–1353 (2012).
199. Steentoft, C. *et al.* Mining the *O*-glycoproteome using zinc-finger nuclease-glycoengineered SimpleCell lines. *Nat. Methods* **8**, 977–982 (2011).
Describes the development of the SimpleCell strategy using zinc-finger nucleases for the characterization of the *O*-glycoproteome of cancer cells.
200. Campos, D. *et al.* Probing the *O*-glycoproteome of gastric cancer cell lines for biomarker discovery. *Mol. Cell. Proteomics* **14**, 1616–1629 (2015).
Details the characterization of the *O*-glycoproteome of gastric cancer cells and serum from patients with gastric cancer.
201. Lauc, G. *et al.* Genomics meets glycomics — the first GWAS study of human *N*-glycome identifies HNF1α as a master regulator of plasma protein fucosylation. *PLoS Genet.* **6**, e1001256 (2010).
202. Miyoshi, E. & Nakano, M. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. *Proteomics* **8**, 3257–3262 (2008).
203. Gomes, C. *et al.* Glycoproteomic analysis of serum from patients with gastric precancerous lesions. *J. Proteome Res.* **12**, 1454–1466 (2013).
204. Saldova, R., Fan, Y., Fitzpatrick, J. M., Watson, R. W. & Rudd, P. M. Core fucosylation and α2-3 sialylation in serum *N*-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. *Glycobiology* **21**, 195–205 (2011).
205. Melo, S. A. *et al.* Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature* **523**, 177–182 (2015).
206. Blixt, O. *et al.* Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. *Breast Cancer Res.* **13**, R25 (2011).
207. Pedersen, J. W. *et al.* Cancer-associated autoantibodies to MUC1 and MUC4 — a blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. *Int. J. Cancer* **134**, 2180–2188 (2014).
208. Moloney, D. J. *et al.* Mammalian Notch1 is modified with two unusual forms of *O*-linked glycosylation found on epidermal growth factor-like modules. *J. Biol. Chem.* **275**, 9604–9611 (2000).
209. Panin, V. M., Papayannopoulos, V., Wilson, R. & Irvine, K. D. Fringe modulates Notch-ligand interactions. *Nature* **387**, 908–912 (1997).
210. Cohen, B. *et al.* Fringe boundaries coincide with Notch-dependent patterning centres in mammals and alter Notch-dependent development in *Drosophila*. *Nat. Genet.* **16**, 283–288 (1997).
211. Tanaka, H. *et al.* Acute myelogenous leukemia with *PIG-A* gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. *Int. J. Hematol.* **73**, 206–212 (2001).
212. Ilver, D. *et al. Helicobacter pylori* adhesin binding fucosylated histo-blood group antigens revealed by retagging. *Science* **279**, 373–377 (1998).
213. Mahdavi, J. *et al. Helicobacter pylori* SabA adhesin in persistent infection and chronic inflammation. *Science* **297**, 573–578 (2002).
214. Magalhaes, A., Ismail, M. N. & Reis, C. A. Sweet receptors mediate the adhesion of the gastric pathogen *Helicobacter pylori*: glycoproteomic strategies. *Expert Rev. Proteomics* **7**, 307–310 (2010).
215. Sarrats, A. *et al.* Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. *Proteomics Clin. Appl.* **4**, 432–448 (2010).
216. Dias, A. M. *et al.* Dysregulation of T cell receptor *N*-glycosylation: a molecular mechanism involved in ulcerative colitis. *Hum. Mol. Genet.* **23**, 2416–2427 (2014).
217. Samraj, A. N. *et al.* A red meat-derived glycan promotes inflammation and cancer progression. *Proc. Natl Acad. Sci. USA* **112**, 542–547 (2015).
218. Chou, H. H. *et al.* A mutation in human CMP-sialic acid hydroxylase occurred after the *Homo-Pan* divergence. *Proc. Natl Acad. Sci. USA* **95**, 11751–11756 (1998).
219. Ychou, M., Duffour, J., Kramar, A., Gourgou, S. & Grenier, J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. *Dis. Markers* **16**, 105–110 (2000).
220. Valmu, L., Alfthan, H., Hotakainen, K., Birken, S. & Stenman, U. H. Site-specific glycan analysis of human chorionic gonadotropin β-subunit from malignancies and pregnancy by liquid chromatography — electrospray mass spectrometry. *Glycobiology* **16**, 1207–1218 (2006).

Acknowledgements
The Institute of Molecular Pathology and Immunology of the University of Porto integrates the Institute for Research and Innovation in Health, which is partially supported by the Portuguese Foundation for Science and Technology (FCT). This work is funded by the European Regional Development Fund (FEDER) through the Operational Programme for Competitiveness Factors (COMPETE) and by national funds through the FCT, under the projects PEst-C/SAU/LA0003/2013, PTDC/BBB-EBI/0786/2012 and EXPL/BIM-MEC/0149/2012. S.S.P. acknowledges a grant from the FCT (number SFRH/BPD/63094/2009). C.A.R. acknowledges support from the European Union Seventh Framework Programme GastricGlycoExplorer (grant number 316929). The authors apologize that they cannot include all the relevant studies on glycosylation in cancer in this article owing to limitation of space. The authors thank Tiago Fontes-Oliveira for support in figures preparations.

Competing interests statement
The authors declare no competing interests.

DATABASES
National Cancer Institute Drug Dictionary: http://www.cancer.gov/drugdictionary
Pathway Interaction Database: http://pid.nci.nih.gov

ALL LINKS ARE ACTIVE IN THE ONLINE PDF